



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits

Preview/Index

History

Clipboard

Details

☐ 1: AX816067. Sequence 3 from P...[gi:39646663]

Links

LOCUS AX816067 20 bp DNA linear PAT 09-DEC-2003

DEFINITION Sequence 3 from Patent WO03066649.

ACCESSION AX816067

VERSION AX816067.1 GI:39646663

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Jiang,Z.H., Koganty,R.R., Yalamati,D. and Baek,M.G.

TITLE Immunostimulatory, covalently lipidated oligonucleotides

JOURNAL Patent: WO 03066649-A 3 14-AUG-2003;

Biomira Inc. (CA)

FEATURES

Location/Qualifiers

source

1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="activating sequence"

ORIGIN

1 ggtgcatcga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Nucleotide

Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AR340848. Sequence 8 from p...[gi:33732695]

LOCUS AR340848 39 bp DNA linear PAT 17-AUG-2003

DEFINITION Sequence 8 from patent US 6573071.

ACCESSION AR340848

VERSION AR340848.1 GI:33732695

KEYWORDS .

SOURCE Unknown.

ORGANISM Unknown.

Unclassified.

REFERENCE 1 (bases 1 to 39)

AUTHORS Himmelspace, M., Schlokat, U., Dorner, F., Fisch, A. and Eibl, J.

TITLE Factor X analogues with a modified protease cleavage site

JOURNAL Patent: US 6573071-A 8 03-JUN-2003;

FEATURES Location/Qualifiers

source 1..39

/organism="unknown"

/mol_type="genomic DNA"

ORIGIN

1 accagaatcg attcttcott gggggttgtc gccctctc

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

default

Show: 20

Send to

File

Get Subsequence

Feat

☐ 1: AX547938. Sequence 1077 fro...[gi:25813082]

Links

LOCUS AX547938 27 bp DNA linear PAT 01-MAR-2003

DEFINITION Sequence 1077 from Patent WO02053141.

ACCESSION AX547938

VERSION AX547938.1 GI:25813082

KEYWORDS

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Bratzler, R.L.

TITLE Inhibition of angiogenesis by nucleic acids

JOURNAL Patent: WO 02053141-A 1077 11-JUL-2002;

Coley Pharmaceutical Group, Inc. (US)

FEATURES Location/Qualifiers

source

1..27

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic Sequence"

ORIGIN

1 ggggtcgacg tcgacgtcga gggggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: BD070374. Factor X-analogue...[gi:22615977]

Links

LOCUS BD070374 39 bp DNA linear PAT 27-AUG-2002

DEFINITION Factor X-analogues with modified protease cleavage site.

ACCESSION BD070374

VERSION BD070374.1 GI:22615977

KEYWORDS JP 2001513631-A/8.

SOURCE unidentified

ORGANISM unidentified

unclassified.

REFERENCE 1 (bases 1 to 39)

AUTHORS Himmelspace, M., Schlokot, U., Dorner, F., Andreas, Fisch and Eibl, J.

TITLE Factor X-analogues with modified protease cleavage site

JOURNAL Patent: JP 2001513631-A 8 04-SEP-2001;

BAXTER AG

COMMENT OS Unidentified

PN JP 2001513631-A/8

PD 04-SEP-2001

PF 27-FEB-1998 JP 1998537062

PR 27-FEB-1997 AT A 335/97

PI MICHELE HIMMELSPACH, UWE SCHLOKAT, FRIEDRICH DORNER, ANDREAS PI
FISCH, JOHANN EIBL

PC C12N15/57, C12N9/64, A61K38/48

CC Strandedness: Single;

CC Topology: Linear;

CC Factor X-analogues with modified protease cleavage site FH

Key Location/Qualifiers

FT source 1..39

FT /organism='Unidentified'.

FEATURES Location/Qualifiers

source 1..39

/organism="unidentified"

/mol_type="genomic DNA"

/db_xref="taxon:32644"

ORIGIN

1 accagaatcg attcttctt ggggttgc gccctctc

//

Disclaimer | Write to the Help Desk

NCBI | NLM | NIH

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX465423. Sequence 91 from ...[gi:21899786]

Links

LOCUS AX465423 19 bp DNA linear PAT 16-JUL-2002

DEFINITION Sequence 91 from Patent WO0211761.

ACCESSION AX465423

VERSION AX465423.1 GI:21899786

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Prince, G. and Klinman, D.M.

TITLE Vaccine against RSV

JOURNAL Patent: WO 0211761-A 91 14-FEB-2002;

HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY
MEDICINE (US)

FEATURES

Location/Qualifiers

source

1..19

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic oligonucleotide"



ORIGIN

1 ggtgcatcga tgcagggg

//

Disclaimer | Write to the Help Desk
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12

Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits Preview/Index History Clipboard Details

Show:

☐ 1: AX465422. Sequence 90 from ...[gi:21899785] [Links](#)

LOCUS AX465422 20 bp DNA linear PAT 16-JUL-2002

DEFINITION Sequence 90 from Patent WO0211761.

ACCESSION AX465422

VERSION AX465422.1 GI:21899785

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Prince, G. and Klinman, D.M.

TITLE Vaccine against RSV

JOURNAL Patent: WO 0211761-A 90 14-FEB-2002;
HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY
MEDICINE (US)

FEATURES Location/Qualifiers

source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide"

ORIGIN

1 ggtgcatcga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits

Preview/Index

History

Clipboard

Details

☐ 1: AX465403. Sequence 71 from ...[gi:21899766]

Links

LOCUS AX465403 19 bp DNA linear PAT 16-JUL-2002

DEFINITION Sequence 71 from Patent WO0211761.

ACCESSION AX465403

VERSION AX465403.1 GI:21899766

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Prince, G. and Klinman, D.M.

TITLE Vaccine against RSV

JOURNAL Patent: WO 0211761-A 71 14-FEB-2002;

HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY
MEDICINE (US)

FEATURES Location/Qualifiers

source 1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide"


ORIGIN

1 ggtgcatcga tgcaggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX465393. Sequence 61 from ...[gi:21899756]

Links

LOCUS AX465393 20 bp DNA linear PAT 16-JUL-2002

DEFINITION Sequence 61 from Patent WO0211761.

ACCESSION AX465393

VERSION AX465393.1 GI:21899756

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Prince, G. and Klinman, D.M.

TITLE Vaccine against RSV

JOURNAL Patent: WO 0211761-A 61 14-FEB-2002;

HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY
MEDICINE (US)

FEATURES

source

Location/Qualifiers

1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic oligonucleotide"

ORIGIN

1 ggtgcatcga tgcagggggg

//

Disclaimer | Write to the Help Desk
NCBI |.nlm | NIH

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX465392. Sequence 60 from ...[gi:21899755]

Links

LOCUS AX465392 20 bp DNA linear PAT 16-JUL-2002

DEFINITION Sequence 60 from Patent WO0211761.

ACCESSION AX465392

VERSION AX465392.1 GI:21899755

KEYWORDS

SOURCE synthetic construct

ORGANISM synthetic construct

artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Prince, G. and Klinman, D.M.

TITLE Vaccine against RSV

JOURNAL Patent: WO 0211761-A 60 14-FEB-2002;

HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY
MEDICINE (US)

FEATURES

Location/Qualifiers

source

1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic oligonucleotide"

ORIGIN

1 ggtgcaccgg tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

default

Show:

20

Send to

File

Get Subsequence

Feat

☐ 1: AX465391. Sequence 59 from ...[gi:21899754]

Links

LOCUS AX465391 20 bp DNA linear PAT 16-JUL-2002

DEFINITION Sequence 59 from Patent WO0211761.

ACCESSION AX465391

VERSION AX465391.1 GI:21899754

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Prince, G. and Klinman, D.M.

TITLE Vaccine against RSV

JOURNAL Patent: WO 0211761-A 59 14-FEB-2002;

HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY
MEDICINE (US)

FEATURES

Location/Qualifiers

source

1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic oligonucleotide"




ORIGIN

1 ggtgcgtcga cgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12

   Nucleotide

Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits Preview/Index History Clipboard Details

Show:

☐ 1: AX465388. Sequence 56 from ...[gi:21899751] [Links](#)

LOCUS AX465388 20 bp DNA linear PAT 16-JUL-2002

DEFINITION Sequence 56 from Patent WO0211761.

ACCESSION AX465388

VERSION AX465388.1 GI:21899751

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct

artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Prince, G. and Klinman, D.M.

TITLE Vaccine against RSV

JOURNAL Patent: WO 0211761-A 56 14-FEB-2002;

HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY

MEDICINE (US)

FEATURES Location/Qualifiers

source 1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic oligonucleotide"


ORIGIN

1 ggtgcatcga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits

Preview/Index

History

Clipboard

Details

Show:

☐ 1: AX465387. Sequence 55 from ...[gi:21899750]

Links

LOCUS AX465387 20 bp DNA linear PAT 16-JUL-2002

DEFINITION Sequence 55 from Patent WO0211761.

ACCESSION AX465387

VERSION AX465387.1 GI:21899750

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Prince, G. and Klinman, D.M.

TITLE Vaccine against RSV

JOURNAL Patent: WO 0211761-A 55 14-FEB-2002;

HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY
MEDICINE (US)

FEATURES

source

Location/Qualifiers

1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic oligonucleotide"


ORIGIN

1 ggtgcatcga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Limits

Preview/Index

History

Clipboard

Details

 ☐ 1: AX465384. Sequence 52 from ...[gi:21899747]

Links

LOCUS AX465384 20 bp DNA linear PAT 16-JUL-2002

DEFINITION Sequence 52 from Patent WO0211761.

ACCESSION AX465384

VERSION AX465384.1 GI:21899747

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Prince, G. and Klinman, D.M.

TITLE Vaccine against RSV

JOURNAL Patent: WO 0211761-A 52 14-FEB-2002;

HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY
MEDICINE (US)

FEATURES Location/Qualifiers

source 1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic oligonucleotide"


ORIGIN

1 ggtgcatcga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12

[Entrez](#)[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[PMC](#)[Taxonomy](#)[Book](#)Search for [Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)

Show:

☐ 1: AX465382. Sequence 50 from ...[gi:21899745][Links](#)

LOCUS AX465382 20 bp DNA linear PAT 16-JUL-2002

DEFINITION Sequence 50 from Patent WO0211761.

ACCESSION AX465382

VERSION AX465382.1 GI:21899745

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct

artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Prince, G. and Klinman, D.M.

TITLE Vaccine against RSV

JOURNAL Patent: WO 0211761-A 50 14-FEB-2002;

HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY
MEDICINE (US)

FEATURES Location/Qualifiers

source

1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic oligonucleotide"

ORIGIN

1 ggtgcatcga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits

Preview/Index

History

Clipboard

Details

☐ 1: AX352255. Sequence 551 from...[gi:18617538]

Links

LOCUS AX352255 18 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 551 from Patent WO0193902.

ACCESSION AX352255

VERSION AX352255.1 GI:18617538

KEYWORDS

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 551 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic HDR"

ORIGIN


1 tgcategatg cagggggg


//

[Disclaimer](#) | [Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12





Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search

Nucleotide

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

default

Show:

20

Send to

File

Get Subsequence

Feat

☐ 1: AX352254. Sequence 550 from...[gi:18617537]

Links

LOCUS AX352254 20 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 550 from Patent WO0193902.

ACCESSION AX352254

VERSION AX352254.1 GI:18617537

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond,J.J., Flora,M. and Klinman,D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 550 13-DEC-2001;
Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic HDR"

ORIGIN

1 aatgcatega tgcagggggg

//

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX352253. Sequence 549 from...[gi:18617536]

Links

LOCUS AX352253 17 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 549 from Patent WO0193902.

ACCESSION AX352253

VERSION AX352253.1 GI:18617536

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct

artificial sequences.

REFERENCE 1

AUTHORS Mond,J.J., Flora,M. and Klinman,D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 549 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source

1..17

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"

ORIGIN

1 tgcacgatg caggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search **Nucleotide** for

Limits

Preview/Index

History

Clipboard

Details

default

Show:

20

File

☐ 1: AX352252. Sequence 548 from...[gi:18617535]

Links

LOCUS AX352252 40 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 548 from Patent WO0193902.

ACCESSION AX352252

VERSION AX352252.1 GI:18617535

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 548 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES

Location/Qualifiers

source

1..40

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"

ORIGIN

1 tatatatccc cccggtgcac cgggtgcaggg gggatatata

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX352250. Sequence 546 from...[gi:18617533]

Links

LOCUS AX352250 20 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 546 from Patent WO0193902.

ACCESSION AX352250

VERSION AX352250.1 GI:18617533

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 546 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"

ORIGIN

1 aatgcacgga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Limits

Preview/Index

History

Clipboard

Details

 ☐ 1: AX352249. Sequence 545 from...[gi:18617532]

Links

LOCUS AX352249 17 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 545 from Patent WO0193902.

ACCESSION AX352249

VERSION AX352249.1 GI:18617532

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 545 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..17

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"

ORIGIN

1 tgcacgcatg caggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12

[Entrez](#)[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[PMC](#)[Taxonomy](#)[Book](#)Search for [Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)

Show:

☐ 1: AX352248. Sequence 544 from...[gi:18617531][Links](#)

LOCUS AX352248 22 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 544 from Patent WO0193902.

ACCESSION AX352248

VERSION AX352248.1 GI:18617531

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 544 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..22
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic HDR"

ORIGIN

1 ggggtgcac gatgcagggg gg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits

Preview/Index

History

Clipboard

Details

☐ 1: AX352244. Sequence 540 from...[gi:18617527]

Links

LOCUS AX352244 20 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 540 from Patent WO0193902.

ACCESSION AX352244

VERSION AX352244.1 GI:18617527

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 540 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"

ORIGIN

1 ggtgcaccgg tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits

Preview/Index

History

Clipboard

Details

Show:

☐ 1: AX352242. Sequence 538 from...[gi:18617525]

Links

LOCUS AX352242 20 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 538 from Patent WO0193902.

ACCESSION AX352242

VERSION AX352242.1 GI:18617525

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct

artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 538 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"

ORIGIN



1 ggtgcatcga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12

  **Nucleotide**

Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits Preview/Index History Clipboard Details

Show:

☐ 1: AX352241. Sequence 537 from...[gi:18617524]

LOCUS AX352241 28 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 537 from Patent WO0193902.

ACCESSION AX352241

VERSION AX352241.1 GI:18617524

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 537 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..28

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"

ORIGIN

1 tcaacgttgg tgcaccggtg cagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits

Preview/Index

History

Clipboard

Details

 Show: ☐ 1: AX352240. Sequence 536 from...[gi:18617523]

Links

LOCUS AX352240 26 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 536 from Patent WO0193902.

ACCESSION AX352240

VERSION AX352240.1 GI:18617523

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 536 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..26

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"


ORIGIN

1 tcaacgtttg catogatgca gggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits

Preview/Index

History

Clipboard

Details

Show:

☐ 1: AX352239. Sequence 535 from...[gi:18617522]

Links

LOCUS AX352239 28 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 535 from Patent WO0193902.

ACCESSION AX352239

VERSION AX352239.1 GI:18617522

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 535 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..28
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic HDR"

ORIGIN

1 tcaacgttaa tgcacgatg cagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX352238. Sequence 534 from...[gi:18617521]

Links

LOCUS AX352238 25 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 534 from Patent WO0193902.

ACCESSION AX352238

VERSION AX352238.1 GI:18617521

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 534 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source

1..25

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"



ORIGIN

1 tcaacgtttg catcgatgca ggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12

  Nucleotide

Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits Preview/Index History Clipboard Details

Show:

☐ 1: AX352237. Sequence 533 from...[gi:18617520]

LOCUS AX352237 29 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 533 from Patent WO0193902.

ACCESSION AX352237

VERSION AX352237.1 GI:18617520

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 533 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..29
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic HDR"

ORIGIN

1 tcaacgttgg gtgcatcgat gcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX352233. Sequence 529 from...[gi:18617516]

Links

LOCUS AX352233 28 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 529 from Patent WO0193902.

ACCESSION AX352233

VERSION AX352233.1 GI:18617516

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 529 13-DEC-2001;
Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..28

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"



ORIGIN

1 tcaacgttgg tgcaccggtg cagggggg

//

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

Jun 8 2004 17:01:12

  Nucleotide

Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits Preview/Index History Clipboard Details

Show:

☐ 1: AX352231. Sequence 527 from...[gi:18617514] [Links](#)

LOCUS AX352231 28 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 527 from Patent WO0193902.

ACCESSION AX352231

VERSION AX352231.1 GI:18617514

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 527 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source
1..28
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic HDR"



ORIGIN

1 tcaacgttgg tgcacgatg cagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12

  **Nucleotide**

Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Show:

☐ 1: AX352230. Sequence 526 from...[gi:18617513]

LOCUS AX352230 30 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 526 from Patent WO0193902.

ACCESSION AX352230

VERSION AX352230.1 GI:18617513

KEYWORDS

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 526 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES

source

Location/Qualifiers

1..30

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"

ORIGIN

1 ggggtgcatc gatgcagggg ggaaaaaaaa

//

[Disclaimer](#) | [Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX352229. Sequence 525 from...[gi:18617512]

Links

LOCUS AX352229 28 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 525 from Patent WO0193902.

ACCESSION AX352229

VERSION AX352229.1 GI:18617512

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 525 13-DEC-2001;
Biosynexus Incorporated (US)

FEATURES

source

Location/Qualifiers

1..28

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"

ORIGIN

1 ggtgcaccgg tgcagggggg aaaaaaaa

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Limits

Preview/Index

History

Clipboard

Details

 Show: ☐ 1: AX352228. Sequence 524 from...[gi:18617511]

Links

LOCUS AX352228 26 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 524 from Patent WO0193902.

ACCESSION AX352228

VERSION AX352228.1 GI:18617511

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 524 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES

source

Location/Qualifiers

1..26

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"

ORIGIN

1 tgcacgatg caggggggaa aaaaaa

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Limits

Preview/Index

History

Clipboard

Details

 Show: ☐ 1: AX352227. Sequence 523 from...[gi:18617510]

Links

LOCUS AX352227 28 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 523 from Patent WO0193902.

ACCESSION AX352227

VERSION AX352227.1 GI:18617510

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 523 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source
1..28
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic HDR"

ORIGIN

1 aatgcatcga tgcagggggg aaaaaaaaa

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX352226. Sequence 522 from...[gi:18617509]

Links

LOCUS AX352226 25 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 522 from Patent WO0193902.

ACCESSION AX352226

VERSION AX352226.1 GI:18617509

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 522 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES

source

Location/Qualifiers

1..25

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"

ORIGIN

1 tgcacgatg cagggggaaa aaaaa

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX352225. Sequence 521 from...[gi:18617508]

Links

LOCUS AX352225 30 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 521 from Patent WO0193902.

ACCESSION AX352225

VERSION AX352225.1 GI:18617508

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct

artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 521 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES

source

Location/Qualifiers

1..30

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"

ORIGIN

1 ggggtgcac gatgcaggg ggaaaaaaaa

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits

Preview/Index

History

Clipboard

Details

Show:

☐ 1: AX352221. Sequence 517 from...[gi:18617504]

Links

LOCUS AX352221 28 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 517 from Patent WO0193902.

ACCESSION AX352221

VERSION AX352221.1 GI:18617504

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 517 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..28
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic HDR"

ORIGIN

1 ggtgcaccgg tgcagggggg aaaaaaaa

//

Disclaimer | Write to the Help Desk

NCBI | NLM | NIH

Jun 8 2004 17:01:12



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits

Preview/Index

History

Clipboard

Details

Show:

☐ 1: AX352219. Sequence 515 from...[gi:18617502]

Links

LOCUS AX352219 28 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 515 from Patent WO0193902.

ACCESSION AX352219

VERSION AX352219.1 GI:18617502

KEYWORDS

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.
TITLE Immunostimulatory rna/dna hybrid molecules
JOURNAL Patent: WO 0193902-A 515 13-DEC-2001;
Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..28
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic HDR"



ORIGIN

1 ggtgcatega tgcagggggg aaaaaaaaa

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12

  **Nucleotide**

Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits Preview/Index History Clipboard Details

Show:

☐ 1: AX352218. Sequence 514 from...[gi:18617501]

LOCUS AX352218 20 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 514 from Patent WO0193902.

ACCESSION AX352218

VERSION AX352218.1 GI:18617501

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 514 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic HDR"

ORIGIN

1 ggtgcaccgg tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX352217. Sequence 513 from...[gi:18617500]

Links

LOCUS AX352217 18 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 513 from Patent W00193902.

ACCESSION AX352217

VERSION AX352217.1 GI:18617500

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 513 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..18

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"



ORIGIN

1 tgcacgatg cagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12

  **Nucleotide**

Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits Preview/Index History Clipboard Details

Display Show:

☐ 1: AX352216. Sequence 512 from...[gi:18617499]

LOCUS AX352216 20 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 512 from Patent WO0193902.

ACCESSION AX352216

VERSION AX352216.1 GI:18617499

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 512 13-DEC-2001;
Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic HDR"

ORIGIN

1 aatgcatega tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX352215. Sequence 511 from...[gi:18617498]

Links

LOCUS AX352215 17 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 511 from Patent WO0193902.

ACCESSION AX352215

VERSION AX352215.1 GI:18617498

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 511 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source

1..17

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"


ORIGIN

1 tgcacgatg caggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits

Preview/Index

History

Clipboard

Details

Show:

☐ 1: AX352211. Sequence 507 from...[gi:18617494]

[Links](#)

LOCUS AX352211 20 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 507 from Patent WO0193902.

ACCESSION AX352211

VERSION AX352211.1 GI:18617494

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 507 13-DEC-2001;
Biosynexus Incorporated (US)

FEATURES

source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic HDR"


ORIGIN

1 ggtgcaccgg tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Limits

Preview/Index

History

Clipboard

Details

 ☐ 1: AX352209. Sequence 505 from...[gi:18617492]

Links

LOCUS AX352209 20 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 505 from Patent WO0193902.

ACCESSION AX352209

VERSION AX352209.1 GI:18617492

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 505 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic HDR"

ORIGIN

1 ggtgcatcga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX352208. Sequence 504 from...[gi:18617491]

Links

LOCUS AX352208 20 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 504 from Patent WO0193902.

ACCESSION AX352208

VERSION AX352208.1 GI:18617491

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 504 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES

source

Location/Qualifiers

1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"

ORIGIN

1 ggtgcaccgg tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX352207. Sequence 503 from...[gi:18617490]

Links

LOCUS AX352207 18 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 503 from Patent WO0193902.

ACCESSION AX352207

VERSION AX352207.1 GI:18617490

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 503 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source

1..18

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"




ORIGIN

1 tgcacgatg cagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12

   Nucleotide

Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits Preview/Index History Clipboard Details

Show:

☐ 1: AX352206. Sequence 502 from...[gi:18617489]

LOCUS AX352206 20 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 502 from Patent WO0193902.

ACCESSION AX352206

VERSION AX352206.1 GI:18617489

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct

artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 502 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"


ORIGIN

1 aatgcatcga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX352205. Sequence 501 from...[gi:18617488] Links

LOCUS AX352205 17 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 501 from Patent WO0193902.

ACCESSION AX352205

VERSION AX352205.1 GI:18617488

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond,J.J., Flora,M. and Klinman,D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 501 13-DEC-2001;
Biosynexus Incorporated (US)

FEATURES Location/Qualifiers





source 1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic HDR"

ORIGIN

// 1 tgcacgatg caggggg

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

Jun 8 2004 17:01:12

    **Nucleotide**

Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits Preview/Index History Clipboard Details

Show:

☐ 1: AX352204. Sequence 500 from...[gi:18617487] [Links](#)

LOCUS AX352204 22 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 500 from Patent WO0193902.

ACCESSION AX352204

VERSION AX352204.1 GI:18617487

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 500 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..22
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic HDR"



ORIGIN

1 ggggtgcac gatgcagggg gg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12

  **Nucleotide**

Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits Preview/Index History Clipboard Details

Show:

☐ 1: AX352200. Sequence 496 from...[gi:18617483]

LOCUS AX352200 20 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 496 from Patent WO0193902.

ACCESSION AX352200

VERSION AX352200.1 GI:18617483

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct

artificial sequences.

REFERENCE 1

AUTHORS Mond,J.J., Flora,M. and Klinman,D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 496 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"


ORIGIN

1 ggtgcaccgg tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX352198. Sequence 494 from...[gi:18617481]

Links

LOCUS AX352198 20 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 494 from Patent WO0193902.

ACCESSION AX352198

VERSION AX352198.1 GI:18617481

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 494 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source

1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"

ORIGIN

1 ggtgcatcga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX352167. Sequence 463 from...[gi:18617450]

Links

LOCUS AX352167 32 bp DNA linear PAT 06-FEB-2002

DEFINITION Sequence 463 from Patent WO0193902.

ACCESSION AX352167

VERSION AX352167.1 GI:18617450

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Mond, J.J., Flora, M. and Klinman, D.M.

TITLE Immunostimulatory rna/dna hybrid molecules

JOURNAL Patent: WO 0193902-A 463 13-DEC-2001;

Biosynexus Incorporated (US)

FEATURES Location/Qualifiers

source 1..32

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic HDR"


ORIGIN

1 ggtgcacaga tgcagggggg tcgagcggtc tc

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

☐ 1: AX105138. Sequence 36 from ...[gi:13921288]

Links

LOCUS AX105138 27 bp DNA linear PAT 30-APR-2001

DEFINITION Sequence 36 from Patent WO0122990.

ACCESSION AX105138

VERSION AX105138.1 GI:13921288

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Hartmann,G.D., Bratzler,R.L. and Krieg,A.U.

TITLE Methods related to immunostimulatory nucleic acid-induced
interferon

JOURNAL Patent: WO 0122990-A 36 05-APR-2001;

Coley Pharmaceutical Group, Inc. (US) ; UNIVERSITY OF IOWA RESEARCH
FOUNDATION (US)

FEATURES

Location/Qualifiers

source

1..27

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic Oligonucleotide"

misc_feature

1..2

/note="Backbone has phosphorothioate linkages."

misc_feature

3..21

/note="Backbone has phosphodiester linkages."

misc_feature

22..26

/note="Backbone has phosphorothioate linkages."

misc_feature

27

/note="Backbone has phosphodiester linkages."


ORIGIN

1 ggggtcgacg tcgacgtcga gggggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX194473. Sequence 73 from ...[gi:15385129]

Links

LOCUS AX194473 19 bp DNA linear PAT 28-AUG-2001

DEFINITION Sequence 73 from Patent WO0151500.

ACCESSION AX194473

VERSION AX194473.1 GI:15385129

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Klinman,D., Ishii,K. and Verthelyi,D.

TITLE Oligodeoxynucleotide and its use to induce an immune response

JOURNAL Patent: WO 0151500-A 73 19-JUL-2001;

Secretary of the Department of Health and Human Services (US)

FEATURES Location/Qualifiers

source

1..19

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic DNA"

ORIGIN

1 ggtgcatcga tgcaggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Limits

Preview/Index

History

Clipboard

Details

 Show: ☐ 1: AX194472. Sequence 72 from ...[gi:15385128]

Links

LOCUS AX194472 20 bp DNA linear PAT 28-AUG-2001

DEFINITION Sequence 72 from Patent WO0151500.

ACCESSION AX194472

VERSION AX194472.1 GI:15385128

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Klinman,D., Ishii,K. and Verthelyi,D.

TITLE Oligodeoxynucleotide and its use to induce an immune response

JOURNAL Patent: WO 0151500-A 72 19-JUL-2001;

Secretary of the Department of Health and Human Services (US)

FEATURES Location/Qualifiers

source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic DNA"


ORIGIN

1 ggtgcatcga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX194443. Sequence 43 from ...[gi:15385099]

Links

LOCUS AX194443 20 bp DNA linear PAT 28-AUG-2001

DEFINITION Sequence 43 from Patent WO0151500.

ACCESSION AX194443

VERSION AX194443.1 GI:15385099

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Klinman,D., Ishii,K. and Verthelyi,D.

TITLE Oligodeoxynucleotide and its use to induce an immune response

JOURNAL Patent: WO 0151500-A 43 19-JUL-2001;
Secretary of the Department of Health and Human Services (US)

FEATURES Location/Qualifiers

source

1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic DNA"

ORIGIN

1 ggtgcatcga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLN](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX194441. Sequence 41 from ...[gi:15385097]

Links

LOCUS AX194441 20 bp DNA linear PAT 28-AUG-2001

DEFINITION Sequence 41 from Patent WO0151500.

ACCESSION AX194441

VERSION AX194441.1 GI:15385097

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Klinman,D., Ishii,K. and Verthelyi,D.

TITLE Oligodeoxynucleotide and its use to induce an immune response

JOURNAL Patent: WO 0151500-A 41 19-JUL-2001;
Secretary of the Department of Health and Human Services (US)

FEATURES Location/Qualifiers

source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic DNA"

ORIGIN

1 ggtgcgtcga cgcagggggg

//

Disclaimer | Write to the Help Desk

NCBI | NLM | NIH

Jun 8 2004 17:01:12



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits

Preview/Index

History

Clipboard

Details

☐ 1: AX194438. Sequence 38 from ...[gi:15385094] [Links](#)

LOCUS AX194438 20 bp DNA linear PAT 28-AUG-2001

DEFINITION Sequence 38 from Patent WO0151500.

ACCESSION AX194438

VERSION AX194438.1 GI:15385094

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Klinman,D., Ishii,K. and Verthelyi,D.

TITLE Oligodeoxynucleotide and its use to induce an immune response

JOURNAL Patent: WO 0151500-A 38 19-JUL-2001;

Secretary of the Department of Health and Human Services (US)

FEATURES Location/Qualifiers

source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic DNA"

ORIGIN

1 ggtgcatcga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits

Preview/Index

History

Clipboard

Details

Show:

☐ 1: AX194437. Sequence 37 from ...[gi:15385093]

LOCUS AX194437 20 bp DNA linear PAT 28-AUG-2001

DEFINITION Sequence 37 from Patent WO0151500.

ACCESSION AX194437

VERSION AX194437.1 GI:15385093

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Klinman,D., Ishii,K. and Verthelyi,D.

TITLE Oligodeoxynucleotide and its use to induce an immune response

JOURNAL Patent: WO 0151500-A 37 19-JUL-2001;

Secretary of the Department of Health and Human Services (US)

FEATURES Location/Qualifiers

source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic DNA"


ORIGIN

1 ggtgcatcga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits

Preview/Index

History

Clipboard

Details

 Show: ☐ 1: AX194434. Sequence 34 from ...[gi:15385090]

Links

LOCUS AX194434 20 bp DNA linear PAT 28-AUG-2001

DEFINITION Sequence 34 from Patent WO0151500.

ACCESSION AX194434

VERSION AX194434.1 GI:15385090

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct

artificial sequences.

REFERENCE 1

AUTHORS Klinman,D., Ishii,K. and Verthelyi,D.

TITLE Oligodeoxynucleotide and its use to induce an immune response

JOURNAL Patent: WO 0151500-A 34 19-JUL-2001;

Secretary of the Department of Health and Human Services (US)

FEATURES Location/Qualifiers

source 1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic DNA"


ORIGIN

1 ggtgcatcga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX194453. Sequence 53 from ...[gi:15385109]

Links

LOCUS AX194453 19 bp DNA linear PAT 28-AUG-2001

DEFINITION Sequence 53 from Patent WO0151500.

ACCESSION AX194453

VERSION AX194453.1 GI:15385109

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct

artificial sequences.

REFERENCE 1

AUTHORS Klinman,D., Ishii,K. and Verthelyi,D.

TITLE Oligodeoxynucleotide and its use to induce an immune response

JOURNAL Patent: WO 0151500-A 53 19-JUL-2001;

Secretary of the Department of Health and Human Services (US)

FEATURES Location/Qualifiers

source

1..19

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic DNA"



ORIGIN

1 ggtgcatcga tgcaggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12

  **Nucleotide**

Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits Preview/Index History Clipboard Details

Display Show:

☐ 1: AX194442. Sequence 42 from ...[gi:15385098] [Links](#)

LOCUS AX194442 20 bp DNA linear PAT 28-AUG-2001

DEFINITION Sequence 42 from Patent WO0151500.

ACCESSION AX194442

VERSION AX194442.1 GI:15385098

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Klinman,D., Ishii,K. and Verthelyi,D.

TITLE Oligodeoxynucleotide and its use to induce an immune response

JOURNAL Patent: WO 0151500-A 42 19-JUL-2001;

Secretary of the Department of Health and Human Services (US)

FEATURES

source

Location/Qualifiers

1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic DNA"


ORIGIN

1 ggtgcaccgg tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX194439. Sequence 39 from ...[gi:15385095]

Links

LOCUS AX194439 20 bp DNA linear PAT 28-AUG-2001

DEFINITION Sequence 39 from Patent WO0151500.

ACCESSION AX194439

VERSION AX194439.1 GI:15385095

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Klinman,D., Ishii,K. and Verthelyi,D.

TITLE Oligodeoxynucleotide and its use to induce an immune response

JOURNAL Patent: WO 0151500-A 39 19-JUL-2001;

Secretary of the Department of Health and Human Services (US)

FEATURES Location/Qualifiers

source

1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic DNA"

ORIGIN

1 ggtgcgtcga cgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Show:

Send to

Get Subsequence

Feat

☐ 1: AX194432. Sequence 32 from ...[gi:15385088]

Links

LOCUS AX194432 20 bp DNA linear PAT 28-AUG-2001

DEFINITION Sequence 32 from Patent WO0151500.

ACCESSION AX194432

VERSION AX194432.1 GI:15385088

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Klinman,D., Ishii,K. and Verthelyi,D.

TITLE Oligodeoxynucleotide and its use to induce an immune response

JOURNAL Patent: WO 0151500-A 32 19-JUL-2001;

Secretary of the Department of Health and Human Services (US)

FEATURES Location/Qualifiers

source

1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Synthetic DNA"



ORIGIN

1 ggtgcatcga tgcagggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12

  **Nucleotide**

Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits Preview/Index History Clipboard Details

Show:

☐ 1: AX104885. Sequence 1077 fro...[gi:13921082]

LOCUS AX104885 27 bp DNA linear PAT 30-APR-2001

DEFINITION Sequence 1077 from Patent W00122972.

ACCESSION AX104885

VERSION AX104885.1 GI:13921082

KEYWORDS .

SOURCE synthetic construct

ORGANISM synthetic construct
artificial sequences.

REFERENCE 1

AUTHORS Krieg,A.M., Schetter,C. and Vollmer,J.C.

TITLE Immunostimulatory nucleic acids

JOURNAL Patent: WO 0122972-A 1077 05-APR-2001;

UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
GmbH (DE)

FEATURES

source

Location/Qualifiers

1..27

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"







ORIGIN

1 ggggtcgacg tcgacgtcga gggggg

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12

Entrez PubMed Nucleotide Protein Genome Structure PMC Taxonomy Book

Search for

Limits Preview/Index History Clipboard Details

Show:

☐ 1: AZ615410.1M0444C13R Mouse ...[gi:11737600] Links

IDENTIFIERS

dbGSS Id: 2082430
GSS name: 1M0444C13R
GenBank Acc: AZ615410
GenBank gi: 11737600

CLONE INFO

Clone Id: UUGC1M0444C13 (R)
Insert length: 10000
Plate: 0444 Row: C Column: 13
DNA type: Genomic

PRIMERS

Sequencing: CACACAGGAAACAGCTATGACC

SEQUENCE

GTGCGCCCGGCGGCGGCGCGGTGCGCCGGCCGGGGGGCG
Quality: High quality sequence stops at base: 37

Entry Created: Dec 13 2000
Last Updated: Dec 13 2000

LIBRARY

CLASS: plasmid ends
Lib Name: Mouse 10kb plasmid UUGC1M library
Organism: Mus musculus
Strain: C57BL/6J
Sex: Male
Lab host: E. Coli strain XL10-Gold, T1-resistant, F-
Vector: PWD42nv
Description: Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance.

SUBMITTER

Name: Robert B. Weiss
Lab: University of Utah Genome Center
Institution: University of Utah
Address: Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E.,
SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
E-mail: ddunn@genetics.utah.edu


CITATIONS

Title: Mouse whole genome scaffolding with paired end reads from
10kb plasmid inserts
Authors: Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil
,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen
,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A., Wright,D.,Weiss,R.
Year: 2000
Status: Unpublished

MAP DATA

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Jun 8 2004 17:01:12



Entrez

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

Book

Search for

Limits

Preview/Index

History

Clipboard

Details

 Show: ☐ 1: [AI446513.tj20d05.x1 NCI_CG...](#)[gi:4295736][Links](#)**IDENTIFIERS**

dbEST Id: 2261187
EST name: tj20d05.x1
GenBank Acc: [AI446513](#)
GenBank gi: 4295736

CLONE INFO

Clone Id: IMAGE:2142057 (3')
Source: NCI
DNA type: cDNA

PRIMERS

Sequencing: -40UP from Gibco
PolyA Tail: Unknown

SEQUENCE

AACCGGCCCGCCCGGCCGCGGAAAAAGGGG
Quality: Trace considered overall poor quality.

Entry Created: Feb 23 1999
Last Updated: Mar 9 1999

COMMENTS

Tissue Procurement: Christopher Moskaluk, M.D., Ph.D.,
Michael R. Emmert-Buck, M.D., Ph.D.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing
Center
Clone distribution: NCI-CGAP clone distribution information
can be found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/bbrp/image/image.html
Trace considered overall poor quality

PUTATIVE ID Assigned by submitter
SW:CA11_CHICK P02457 PROCOLLAGEN ALPHA 1(I) CHAIN PRECURSOR.
;

LIBRARY

Lib Name: NCI_CGAP_Gas4
Organism: [Homo sapiens](#)
Organ: stomach
Tissue type: poorly differentiated adenocarcinoma with signet ring cell
features
Lab host: DH10B
Vector: pCMV-SPORT6
R. Site 1: SalI
R. Site 2: NotI

Description: Cloned unidirectionally. Primer: Oligo dT. Average insert size 1.69 kb. Life Technologies catalog #: 11549-011

SUBMITTER

Name: Robert Strausberg, Ph.D.
E-mail: cgapbs-r@mail.nih.gov

CITATIONS

Title: National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
Authors: NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>
Year: 1997
Status: Unpublished

MAP DATA

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

Jun 8 2004 17:01:12

=> fil reg; d que l15
 FILE 'REGISTRY' ENTERED AT 14:49:41 ON 01 JUL 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JUN 2004 HIGHEST RN 701907-96-2
 DICTIONARY FILE UPDATES: 30 JUN 2004 HIGHEST RN 701907-96-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

L6 2660919 SEA FILE=REGISTRY ABB=ON SQL<43 AND SQL>16 - *Sequence length limited to*
 L7 847 SEA FILE=REGISTRY ABB=ON L6 AND NNNACCGGTNNNN{0-10}G{4-10}|NNN *greater*
 ATCGATNNNN{0-10}G{4-10}|NNNGCCGGCNNNN{0-10}G{4-10}|NNNGTCGACNNN *than 16 nt*
 N{0-10}G{4-10}/SQSN
 L11 368 SEA FILE=REGISTRY ABB=ON L7 AND NNARYCGRYTNNN{0-10}G{4-10}|NNT *but less*
 RYCGRYANN{0-10}G{4-10}|NNCRYCGRYGNN{0-10}G{4-10}|NNGRYCGRYCNN *than 43 nt*
 N{0-10}G{4-10}/SQSN
 L13 266 SEA FILE=REGISTRY ABB=ON L11 AND NANRYCGRYNTNN{0-10}G{4-10}|NT
 NRYCGRYNANN{0-10}G{4-10}|NCNRYCGRYNGNN{0-10}G{4-10}|NGNRYCGRYNC
 NN{0-10}G{4-10}/SQSN
 L14 178 SEA FILE=REGISTRY ABB=ON L13 AND ANNRYCGRYNNTN{0-10}G{4-10}|TN
 NRYCGRYNNAN{0-10}G{4-10}|CNNRYCGRYNNGN{0-10}G{4-10}|GNNRYCGRYNN
 CN{0-10}G{4-10}/SQSN
 L15 70 SEA FILE=REGISTRY ABB=ON L14 AND GENBANK/LC

=> d in l15 1-70

L15 ANSWER 1 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
 IN GenBank AX816067 (9CI)

L15 ANSWER 2 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
 IN GenBank AR340848 (9CI)

L15 ANSWER 3 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
 IN GenBank AX547938 (9CI)

L15 ANSWER 4 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
 IN GenBank BD070374 (9CI)

L15 ANSWER 5 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
 IN GenBank AX465423 (9CI)

L15 ANSWER 6 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
 IN GenBank AX465422 (9CI)

L15 ANSWER 7 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN

*all answers from
 GenBank*

*GenBank
 accession #'s*

IN GenBank AX465403 (9CI)

L15 ANSWER 8 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX465393 (9CI)

L15 ANSWER 9 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX465392 (9CI)

L15 ANSWER 10 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX465391 (9CI)

L15 ANSWER 11 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX465389 (9CI)

L15 ANSWER 12 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX465388 (9CI)

L15 ANSWER 13 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX465387 (9CI)

L15 ANSWER 14 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX465384 (9CI)

L15 ANSWER 15 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX465382 (9CI)

L15 ANSWER 16 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352255 (9CI)

L15 ANSWER 17 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352254 (9CI)

L15 ANSWER 18 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352253 (9CI)

L15 ANSWER 19 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352252 (9CI)

L15 ANSWER 20 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352250 (9CI)

L15 ANSWER 21 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352249 (9CI)

L15 ANSWER 22 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352248 (9CI)

L15 ANSWER 23 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352244 (9CI)

L15 ANSWER 24 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352242 (9CI)

L15 ANSWER 25 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352241 (9CI)

L15 ANSWER 26 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352240 (9CI)

L15 ANSWER 27 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352239 (9CI)

L15	ANSWER 28 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352238	(9CI)	
L15	ANSWER 29 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352237	(9CI)	
L15	ANSWER 30 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352233	(9CI)	
L15	ANSWER 31 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352231	(9CI)	
L15	ANSWER 32 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352230	(9CI)	
L15	ANSWER 33 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352229	(9CI)	
L15	ANSWER 34 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352228	(9CI)	
L15	ANSWER 35 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352227	(9CI)	
L15	ANSWER 36 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352226	(9CI)	
L15	ANSWER 37 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352225	(9CI)	
L15	ANSWER 38 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352221	(9CI)	
L15	ANSWER 39 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352219	(9CI)	
L15	ANSWER 40 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352218	(9CI)	
L15	ANSWER 41 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352217	(9CI)	
L15	ANSWER 42 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352216	(9CI)	
L15	ANSWER 43 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352215	(9CI)	
L15	ANSWER 44 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352211	(9CI)	
L15	ANSWER 45 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352209	(9CI)	
L15	ANSWER 46 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352208	(9CI)	
L15	ANSWER 47 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352207	(9CI)	
L15	ANSWER 48 OF 70	REGISTRY	COPYRIGHT 2004 ACS on STN
IN	GenBank AX352206	(9CI)	

L15 ANSWER 49 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352205 (9CI)

L15 ANSWER 50 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352204 (9CI)

L15 ANSWER 51 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352200 (9CI)

L15 ANSWER 52 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352198 (9CI)

L15 ANSWER 53 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX352167 (9CI)

L15 ANSWER 54 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX105138 (9CI)

L15 ANSWER 55 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX194473 (9CI)

L15 ANSWER 56 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX194472 (9CI)

L15 ANSWER 57 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX194443 (9CI)

L15 ANSWER 58 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX194441 (9CI)

L15 ANSWER 59 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX194438 (9CI)

L15 ANSWER 60 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX194437 (9CI)

L15 ANSWER 61 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX194434 (9CI)

L15 ANSWER 62 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX194453 (9CI)

L15 ANSWER 63 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX194442 (9CI)

L15 ANSWER 64 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX194439 (9CI)

L15 ANSWER 65 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX194432 (9CI)

L15 ANSWER 66 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AX104885 (9CI)

L15 ANSWER 67 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank AZ615410 (9CI)

L15 ANSWER 68 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN
IN GenBank A86868 (9CI)

L15 ANSWER 69 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN

IN GenBank AI446513 (9CI)

L15 ANSWER 70 OF 70 REGISTRY COPYRIGHT 2004 ACS on STN

IN GenBank AR009571 (9CI)

=> s l14 not l15

L17 108 L14 NOT L15 — all non-GenBank records

=> d sqide l17 1-108

L17 ANSWER 1 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 700878-96-2 REGISTRY — use Registry # to match sequence to citation

CN INDEX NAME NOT YET ASSIGNED

FS NUCLEIC ACID SEQUENCE

SQL 20

NA 2 a 4 c 12 g 2 t

NTE modified

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-2 - t-3	P-thio
modified link	g-15 - g-16	P-thio
modified link	g-16 - g-17	P-thio
modified link	g-17 - g-18	P-thio
modified link	g-18 - g-19	P-thio
modified link	g-19 - g-20	P-thio

SEQ 1 ggtgcaccgg tgcagggggg
=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CAPLUS

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 2 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 700878-95-1 REGISTRY

CN INDEX NAME NOT YET ASSIGNED

FS NUCLEIC ACID SEQUENCE

SQL 20

NA 3 a 3 c 11 g 3 t

NTE modified

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-18 - g-19	P-thio
modified link	g-19 - g-20	P-thio

SEQ 1 ggtgcatcga tgcagggggg
=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CAPLUS

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 3 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 700878-94-0 REGISTRY

CN INDEX NAME NOT YET ASSIGNED

FS NUCLEIC ACID SEQUENCE

SQL 20

NA 3 a 3 c 11 g 3 t

NTE modified

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-2 - t-3	P-thio
modified link	g-15 - g-16	P-thio
modified link	g-16 - g-17	P-thio
modified link	g-17 - g-18	P-thio
modified link	g-18 - g-19	P-thio
modified link	g-19 - g-20	P-thio

SEQ 1 ggtgcatcga tgcagggggg

=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CAPLUS

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 4 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 698754-77-7 REGISTRY

CN DNA, d(G-G-T-G-C-A-C-C-G-G-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)

FS NUCLEIC ACID SEQUENCE

SQL 20

NA 2 a 4 c 12 g 2 t

SEQ 1 ggtgcaccgg tgcagggggg

=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CAPLUS

DT.CA Caplus document type: Patent

RL.P Roles from patents: PRP (Properties)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 5 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 698754-76-6 REGISTRY
 CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 3 c 11 g 3 t

SEQ 1 ggtgcatcga tgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CAPLUS
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 6 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 698753-95-6 REGISTRY
 CN DNA, d(N-N-T-G-C-A-C-C-G-G-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 2 a 4 c 10 g 2 t 2 n

SEQ 1 nntgcaccgg tgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CAPLUS
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 7 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 698400-54-3 REGISTRY
 CN DNA, d(N-N-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 3 c 9 g 3 t 2 n

SEQ 1 nntgcatcga tgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CAPLUS
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES
 (Uses)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 8 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 698400-48-5 REGISTRY
 CN DNA, d(N-N-T-G-C-G-C-C-G-G-C-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 1 a 5 c 11 g 1 t 2 n
 SEQ 1 nntgcgcccgg cgcagggggg
 =====
 HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CAPLUS
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES
 (Uses)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 9 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 698400-46-3 REGISTRY
 CN DNA, d(N-N-T-G-C-G-T-C-G-A-C-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 2 a 4 c 10 g 2 t 2 n
 SEQ 1 nntgcgtcga cgcagggggg
 =====
 HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CAPLUS
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES
 (Uses)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 10 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 662376-92-3 REGISTRY
 CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 153: PN: WO2004014322 TABLE: 8 unclaimed sequence
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 3 c 11 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2004014322
	unclaimed
	TABLE 8

SEQ 1 ggtgcacga tgcagggggg

ITS AT: 3-20

*RELATED SEQUENCES AVAILABLE WITH SEQLINK**

F Unspecified
I MAN
R CA
C STN Files: CA, CAPLUS
T.CA Caplus document type: Patent
L.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

17 ANSWER 11 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
N 640803-43-6 REGISTRY
N DNA, d(G-sp-G-sp-T-G-C-A-T-C-G-A-T-G-C-A-G-G-sp-G-sp-G-sp-G) (9CI)
(CA INDEX NAME)
S NUCLEIC ACID SEQUENCE
QL 20
A 3 a 3 c 11 g 3 t
ITE modified

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-2 - t-3	P-thio
modified link	g-16 - g-17	P-thio
modified link	g-17 - g-18	P-thio
modified link	g-18 - g-19	P-thio
modified link	g-19 - g-20	P-thio

EQ 1 ggtgcatcga tgcagggggg

ITS AT: 3-20

*RELATED SEQUENCES AVAILABLE WITH SEQLINK**

F Unspecified
I MAN
R CA
C STN Files: CA, CAPLUS
T.CA Caplus document type: Journal
L.NP Roles from non-patents: BIOL (Biological study)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

17 ANSWER 12 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
N 637803-30-6 REGISTRY
N DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
S NUCLEIC ACID SEQUENCE
QL 20
A 3 a 3 c 11 g 3 t

EQ 1 ggtgcatcga tgcagggggg

ITS AT: 3-20

*RELATED SEQUENCES AVAILABLE WITH SEQLINK**

F Unspecified
I MAN
R CA
C STN Files: CA, CAPLUS, TOXCENTER

DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 13 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 631926-12-0 REGISTRY
 CN DNA, d(G-sp-G[oxy(mercaptophosphinylidene)oxy-1,3-
 propanediyl oxy(mercaptophosphinylidene)oxy]T-C-G-T-G-
 C[oxy(mercaptophosphinylidene)oxy-1,3-propanediyl oxy(mercaptophosphinyli-
 de)oxy]A-T-C-G-A-T[oxy(mercaptophosphinylidene)oxy-1,3-
 propanediyl oxy(mercaptophosphinylidene)oxy]G-C-A-C-G-
 A[oxy(mercaptophosphinylidene)oxy-1,3-propanediyl oxy(mercaptophosphinyli-
 de)oxy]G-G-sp-G-sp-G-sp-G-sp-G) (9CI) (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 26
 NA 4 a 5 c 13 g 4 t
 NTE modified

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-22 - g-23	P-thio
modified link	g-23 - g-24	P-thio
modified link	g-24 - g-25	P-thio
modified link	g-25 - g-26	P-thio
uncommon link	g-2 - t-3	unavailable
uncommon link	c-8 - a-9	unavailable
uncommon link	t-14 - g-15	unavailable
uncommon link	a-20 - g-21	unavailable

SEQ 1 ggtcgtgcat cgatgcacga gggggg
 =====
 HITS AT: 6-26

RELATED SEQUENCES AVAILABLE WITH SEQLINK
 MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP
 (Properties); USES (Uses)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 14 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 631926-11-9 REGISTRY
 CN DNA, d(G-sp-G[oxy(mercaptophosphinylidene)oxy-1,3-
 propanediyl oxy(mercaptophosphinylidene)oxy]T-G-
 C[oxy(mercaptophosphinylidene)oxy-1,3-propanediyl oxy(mercaptophosphinyli-
 de)oxy]A-T-C-G-A-T[oxy(mercaptophosphinylidene)oxy-1,3-
 propanediyl oxy(mercaptophosphinylidene)oxy]G-C-
 A[oxy(mercaptophosphinylidene)oxy-1,3-propanediyl oxy(mercaptophosphinyli-
 de)oxy]G-G-sp-G-sp-G-sp-G-sp-G) (9CI) (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 3 c 11 g 3 t
 NTE modified

type	location	description
------	----------	-------------

```

-----
modified link   g-1       - g-2       P-thio
modified link   g-16      - g-17      P-thio
modified link   g-17      - g-18      P-thio
modified link   g-18      - g-19      P-thio
modified link   g-19      - g-20      P-thio
uncommon link   g-2       - t-3       unavailable
uncommon link   c-5       - a-6       unavailable
uncommon link   t-11      - g-12      unavailable
uncommon link   a-14      - g-15      unavailable
-----

```

SEQ 1 ggtgcatcga tgcagggggg

=====

HITS AT: 3-20

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 15 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 573722-83-5 REGISTRY

CN DNA, d(G-sp-G-sp-T-G-C-A-C-C-G-G-T-G-C-A-G-G-sp-G-sp-G-sp-G) (9CI)
(CA INDEX NAME)

FS NUCLEIC ACID SEQUENCE

SQL 20

NA 2 a 4 c 12 g 2 t

NTE modified

```

-----
type           location      description
-----
modified link   g-1       - g-2       P-thio
modified link   g-2       - t-3       P-thio
modified link   g-16      - g-17      P-thio
modified link   g-17      - g-18      P-thio
modified link   g-18      - g-19      P-thio
modified link   g-19      - g-20      P-thio
-----

```

SEQ 1 ggtgcaccgg tgcagggggg

=====

HITS AT: 3-20

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Journal

RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 16 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 573722-82-4 REGISTRY

CN DNA, d(G-sp-G-sp-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-sp-G) (9CI) (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 3 c 11 g 3 t
 NTE modified

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-2 - t-3	P-thio
modified link	g-19 - g-20	P-thio

SEQ 1 ggtgcatcga tgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 17 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 573722-80-2 REGISTRY
 CN DNA, d(G-sp-G-sp-T-G-C-A-T-C-G-A-T-G-C-A-G-G-sp-G-sp-G-sp-G-sp-G) (9CI)
 (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 3 c 11 g 3 t
 NTE modified

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-2 - t-3	P-thio
modified link	g-16 - g-17	P-thio
modified link	g-17 - g-18	P-thio
modified link	g-18 - g-19	P-thio
modified link	g-19 - g-20	P-thio

SEQ 1 ggtgcatcga tgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 18 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 569431-26-1 REGISTRY
 CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 53: PN: US20030144229 SEQID: 53 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 19
 NA 3 a 3 c 10 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2003144229 unclaimed SEQID 53

SEQ 1 ggtgcatcga tgcagggggg
 =====

HITS AT: 3-19

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 19 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 569431-16-9 REGISTRY
 CN DNA, d(G-G-T-G-C-A-C-C-G-G-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 42: PN: US20030144229 SEQID: 42 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 2 a 4 c 12 g 2 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2003144229 unclaimed SEQID 42

SEQ 1 ggtgcaccgg tgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 20 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 569431-14-7 REGISTRY
 CN DNA, d(G-G-T-G-C-G-T-C-G-A-C-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 39: PN: US20030144229 SEQID: 39 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 2 a 4 c 12 g 2 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2003144229 unclaimed SEQID 39

SEQ 1 ggtgcgtcga cgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 21 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 569431-10-3 REGISTRY
 CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 32: PN: US20030144229 SEQID: 32 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 3 c 11 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2003144229 unclaimed SEQID 32

SEQ 1 ggtgcatcga tgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 22 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 552439-63-1 REGISTRY
CN DNA, d(G-G-T-G-G-A-T-C-G-A-T-C-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 24: PN: WO03054161 SEQID: 26 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 3 a 3 c 11 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003054161 unclaimed SEQID 26

SEQ 1 ggtggatcga tccagggggg
=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS
DT.CA Caplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 23 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 552439-62-0 REGISTRY
CN DNA, d(G-G-T-A-T-A-T-C-G-A-T-A-T-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 23: PN: WO03054161 SEQID: 25 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 5 a 1 c 9 g 5 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003054161 unclaimed SEQID 25

SEQ 1 ggtatatcga tatagggggg
=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS

DT.CA CAPlus document type: Patent

RL.P Roles from patents: PRP (Properties)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 24 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 552439-61-9 REGISTRY

CN DNA, d(C-C-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 22: PN: WO03054161 SEQID: 24 unclaimed DNA

FS NUCLEIC ACID SEQUENCE

SQL 20

NA 3 a 5 c 9 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003054161
	unclaimed
	SEQID 24

=====+

Not Given|WO2003054161
unclaimed
SEQID 24

SEQ 1 cctgcatcga tgcagggggg

=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS

DT.CA CAPlus document type: Patent

RL.P Roles from patents: PRP (Properties)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 25 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 552439-56-2 REGISTRY

CN DNA, d(G-G-T-G-C-G-T-C-G-A-C-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 17: PN: WO03054161 SEQID: 19 unclaimed DNA

FS NUCLEIC ACID SEQUENCE

SQL 20

NA 2 a 4 c 12 g 2 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003054161
	unclaimed
	SEQID 19

=====+

Not Given|WO2003054161
unclaimed
SEQID 19

SEQ 1 ggtgcgtcga cgcagggggg

=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE).

L17 ANSWER 26 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 552439-53-9 REGISTRY
 CN DNA, d(T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 14: PN: WO03054161 SEQID: 16 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 18
 NA 3 a 3 c 9 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003054161
	unclaimed
	SEQID 16

SEQ 1 tgcacgatg cagggggg
 =====
 HITS AT: 1-18

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 27 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 552439-50-6 REGISTRY
 CN DNA, d(G-G-T-G-C-A-C-C-G-G-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 11: PN: WO03054161 SEQID: 13 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 2 a 4 c 12 g 2 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003054161
	unclaimed
	SEQID 13

SEQ 1 ggtgcaccgg tgcagggggg
 =====
 HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA CAplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 28 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 552439-49-3 REGISTRY
 CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 10: PN: WO03054161 SEQID: 12 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 3 c 11 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003054161
	unclaimed
	SEQID 12

SEQ 1 ggtgcatcga tgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA CAplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 29 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 537058-59-6 REGISTRY
 CN DNA, d(G-sp-G-sp-T-G-C-A-T-C-G-A-T-G-C-A-G-G-sp-G-sp-G-sp-G) (9CI)
 (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 3 c 11 g 3 t
 NTE modified

type	location		description
modified link	g-1	- g-2	P-thio
modified link	g-2	- t-3	P-thio
modified link	g-16	- g-17	P-thio
modified link	g-17	- g-18	P-thio
modified link	g-18	- g-19	P-thio
modified link	g-19	- g-20	P-thio

SEQ 1 ggtgcatcga tgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 L17 ANSWER 30 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 537058-58-5 REGISTRY
 CN DNA, d(G-sp-G-sp-T-G-C-A-C-C-G-G-T-G-C-A-G-G-sp-G-sp-G-sp-G) (9CI)
 (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 2 a 4 c 12 g 2 t
 NTE modified

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-2 - t-3	P-thio
modified link	g-16 - g-17	P-thio
modified link	g-17 - g-18	P-thio
modified link	g-18 - g-19	P-thio
modified link	g-19 - g-20	P-thio

SEQ 1 ggtgcaccgg tgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 L17 ANSWER 31 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 534784-78-6 REGISTRY
 CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 2: PN: WO03043588 SEQID: 2 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 3 c 11 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
=====	
Not Given	WO2003043588
	unclaimed
	SEQID 2

SEQ 1 ggtgcatcga tgcagggggg

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

DT.CA Caplus document type: Patent

RL.P Roles from patents: PRP (Properties)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 32 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 524986-12-7 REGISTRY

CN DNA, d(G-G-T-G-G-A-T-C-G-A-T-C-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 89: PN: WO03040308 SEQID: 89 unclaimed DNA

FS NUCLEIC ACID SEQUENCE

SQL 20

NA 3 a 3 c 11 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence | Patent

Source | Reference

====+=====

Not Given | WO2003040308

| unclaimed

| SEQID 89

SEQ 1 ggtggatcga tccagggggg

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

DT.CA Caplus document type: Patent

RL.P Roles from patents: PRP (Properties)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 33 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 524986-11-6 REGISTRY

CN DNA, d(G-G-T-A-T-A-T-C-G-A-T-A-T-A-G-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 88: PN: WO03040308 SEQID: 88 unclaimed DNA

FS NUCLEIC ACID SEQUENCE

SQL 20

NA 5 a 1 c 9 g 5 t

PATENT ANNOTATIONS (PNTE):

Sequence | Patent

Source | Reference

====+=====

Not Given | WO2003040308

| unclaimed

|SEQID 88

SEQ 1 ggtatatcga tatagggggg

=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

DT.CA Caplus document type: Patent

RL.P Roles from patents: PRP (Properties)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 34 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 524986-00-3 REGISTRY

CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G-T-G-C-A-G-G-C-T-T-C-T-C)

(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 77: PN: WO03040308 SEQID: 77 unclaimed DNA

FS NUCLEIC ACID SEQUENCE

SQL 32

NA 4 a 7 c 14 g 7 t

PATENT ANNOTATIONS (PNTE):

Sequence | Patent

Source | Reference

=====+

Not Given | WO2003040308

| unclaimed

| SEQID 77

SEQ 1 ggtgcatcga tgcagggggg tgcaggcttc tc

=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

DT.CA Caplus document type: Patent

RL.P Roles from patents: PRP (Properties)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 35 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 524985-99-7 REGISTRY

CN DNA, d(T-C-G-A-G-C-G-T-T-C-T-C-G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G)

(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 76: PN: WO03040308 SEQID: 76 unclaimed DNA

FS NUCLEIC ACID SEQUENCE

SQL 32

NA 4 a 7 c 14 g 7 t

PATENT ANNOTATIONS (PNTE):

Sequence | Patent

Source	Reference
Not Given	WO2003040308
	unclaimed
	SEQID 76

SEQ 1 tcgagcgttc tcggtgcatc gatgcagggg gg
=====

HITS AT: 15-32

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA Caplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 36 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 524985-98-6 REGISTRY
CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-T-C-G-A-G-C-G-T-T-C-T-C)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 75: PN: WO03040308 SEQID: 75 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 32
NA 4 a 7 c 14 g 7 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003040308
	unclaimed
	SEQID 75

SEQ 1 ggtgcatcga tgcagggggg tcgagcgttc tc
=====

HITS AT: 3-20

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA Caplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 37 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 524985-93-1 REGISTRY
CN DNA, d(G-G-T-G-C-G-T-C-G-A-C-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 67: PN: WO03040308 SEQID: 67 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 2 a 4 c 12 g 2 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003040308
	unclaimed
	SEQID 67

SEQ 1 ggtgcgtcga cgcagggggg
=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 38 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 524985-91-9 REGISTRY
CN DNA, d(G-G-T-G-C-A-C-C-G-G-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 65: PN: WO03040308 SEQID: 65 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 2 a 4 c 12 g 2 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003040308
	unclaimed
	SEQID 65

SEQ 1 ggtgcaccgg tgcagggggg
=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 39 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 524985-88-4 REGISTRY
CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 61: PN: WO03040308 SEQID: 61 unclaimed DNA
FS NUCLEIC ACID SEQUENCE

SQL 20
NA 3 a 3 c 11 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003040308
	unclaimed
	SEQID 61

SEQ 1 ggtgcatcga tgcagggggg
=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 40 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 524084-27-3 REGISTRY
CN DNA, d(G-G-G-G-T-C-G-A-C-G-T-C-G-A-C-G-T-C-G-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 420: PN: US20030087848 SEQID: 1077 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 27
NA 3 a 5 c 16 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2003087848
	unclaimed
	SEQID 1077

SEQ 1 ggggtcgacg tcgacgtcga gggggggg
=====

HITS AT: 1-27

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 41 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 503576-65-6 REGISTRY
CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 33: PN: US20030060440 FIGURE: 1 unclaimed sequence
 FS NUCLEIC ACID SEQUENCE
 SQL 18
 NA 3 a 3 c 9 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
=====+	
Not Given	US2003060440
	unclaimed
	FIGURE 1

SEQ 1 ggtgcatcga tgcagggg
 =====

HITS AT: 3-18
 MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 42 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 503576-64-5 REGISTRY
 CN DNA, d(A-A-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 31: PN: US20030060440 FIGURE: 1 unclaimed sequence
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 5 a 3 c 9 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
=====+	
Not Given	US2003060440
	unclaimed
	FIGURE 1

SEQ 1 aatgcatcga tgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 43 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 503576-63-4 REGISTRY
 CN DNA, d(G-G-G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 21: PN: US20030060440 FIGURE: 1 unclaimed sequence
 FS NUCLEIC ACID SEQUENCE
 SQL 22
 NA 3 a 3 c 13 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2003060440 unclaimed FIGURE 1

SEQ 1 ggggtgcatc gatgcagggg gg
 =====
 HITS AT: 5-22

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 44 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 503575-94-8 REGISTRY
 CN DNA, d(G-G-T-G-G-A-T-C-G-A-T-C-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 111: PN: US20030060440 SEQID: 40 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 3 c 11 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2003060440 unclaimed SEQID 40

SEQ 1 ggtggatcga tccagggggg
 =====
 HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 45 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 503575-93-7 REGISTRY
 CN DNA, d(G-G-T-A-T-A-T-C-G-A-T-A-T-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 110: PN: US20030060440 SEQID: 39 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 5 a 1 c 9 g 5 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2003060440 unclaimed SEQID 39

SEQ 1 ggtatatcga tatagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 46 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 503575-92-6 REGISTRY
 CN DNA, d(C-C-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 109: PN: US20030060440 SEQID: 38 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 5 c 9 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2003060440 unclaimed SEQID 38

SEQ 1 cctgcatcga tgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 47 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 503575-76-6 REGISTRY
 CN DNA, d(T-G-C-G-T-C-G-A-C-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 85: PN: US20030060440 SEQID: 14 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 18
 NA 2 a 4 c 10 g 2 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2003060440
	unclaimed
	SEQID 14

SEQ 1 tgcgtcgacg cagggggg
 =====

HITS AT: 1-18
 MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 48 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 503572-73-4 REGISTRY
 CN DNA, d(G-G-T-G-C-G-T-C-G-A-C-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 102: PN: US20030060440 SEQID: 31 claimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 2 a 4 c 12 g 2 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2003060440
	claimed
	SEQID 31

SEQ 1 ggtgcgtcga cgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES
 (Uses)
 1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 49 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 503572-69-8 REGISTRY
 CN DNA, d(T-G-C-G-C-C-G-G-C-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 88: PN: US20030060440 SEQID: 17 claimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 18
 NA 1 a 5 c 11 g 1 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
=====+=====	
Not Given	US2003060440 claimed SEQID 17

SEQ 1 tgcgccggcg cagggggg
 =====

HITS AT: 1-18
 MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES
 (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 50 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 503572-66-5 REGISTRY
 CN DNA, d(T-G-C-A-C-C-G-G-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 84: PN: US20030060440 SEQID: 13 claimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 18
 NA 2 a 4 c 10 g 2 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
=====+=====	
Not Given	US2003060440 claimed SEQID 13

SEQ 1 tgcaccggtg cagggggg
 =====

HITS AT: 1-18
 MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES
 (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 51 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 503572-65-4 REGISTRY
 CN DNA, d(T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 83: PN: US20030060440 SEQID: 12 claimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 18
 NA 3 a 3 c 9 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2003060440 claimed SEQID 12

SEQ 1 tgcacgcatg cagggggg

HITS AT: 1-18

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES
 (Uses)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 52 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 503572-63-2 REGISTRY
 CN DNA, d(G-G-T-G-C-A-C-C-G-G-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 73: PN: US20030060440 SEQID: 2 claimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 2 a 4 c 12 g 2 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2003060440 claimed SEQID 2

SEQ 1 ggtgcaccgg tgcagggggg

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES
 (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 53 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 503572-62-1 REGISTRY
 CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 72: PN: US20030060440 SEQID: 1 claimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 3 c 11 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2003060440
	claimed
	SEQID 1

SEQ 1 ggtgcatcga tgcagggggg
 =====
 HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES
 (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 54 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 501983-30-8 REGISTRY
 CN DNA, d(G-G-G-G-T-C-G-A-C-G-T-C-G-A-C-G-T-C-G-A-G-G-G-G-G-G) (9CI) (CA
 INDEX NAME)
 OTHER NAMES:
 CN 479: PN: US20030050268 SEQID: 1021 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 27
 NA 3 a 5 c 16 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2003050268
	unclaimed
	SEQID 1021

SEQ 1 ggggtcgcgc tgcgcgtcga gggggggg
 =====
 HITS AT: 1-27

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 55 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 501834-44-2 REGISTRY
 CN DNA, d(G-G-T-G-G-A-T-C-G-A-T-C-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 43: PN: WO03020884 SEQID: 43 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 3 c 11 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003020884
	unclaimed
	SEQID 43

SEQ 1 ggtggatcga tccagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 56 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 501834-43-1 REGISTRY
 CN DNA, d(G-G-T-A-T-A-T-C-G-A-T-A-T-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 42: PN: WO03020884 SEQID: 42 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 5 a 1 c 9 g 5 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003020884
	unclaimed
	SEQID 42

SEQ 1 ggtatatcga tatagggggg
 =====

HITS AT: 3-20

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 57 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 501834-32-8 REGISTRY
 CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-T-G-C-A-G-G-C-T-T-C-T-C)
 (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 31: PN: WO03020884 SEQID: 31 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 32
 NA 4 a 7 c 14 g 7 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003020884
	unclaimed
	SEQID 31

SEQ 1 ggtgcatcga tgcagggggg tgcaggcttc tc*
 =====

HITS AT: 3-20

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 58 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 501834-31-7 REGISTRY
 CN DNA, d(T-C-G-A-G-C-G-T-T-C-T-C-G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G)
 (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 30: PN: WO03020884 SEQID: 30 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 32
 NA 4 a 7 c 14 g 7 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003020884
	unclaimed
	SEQID 30

SEQ 1 tcgagcggttc tcggtgcate gatgcagggg gg
=====

HITS AT: 15-32

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS
DT.CA Cplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 59 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 501834-30-6 REGISTRY
CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-T-C-G-A-G-C-G-T-T-C-T-C)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 29: PN: WO03020884 SEQID: 29 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 32
NA 4 a 7 c 14 g 7 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003020884
	unclaimed
	SEQID 29

SEQ 1 ggtgcacga tgcagggggg tcgagcggttc tc
=====

HITS AT: 3-20

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS
DT.CA Cplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 60 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 501834-25-9 REGISTRY
CN DNA, d(G-G-T-G-C-G-T-C-G-A-C-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
OTHER NAMES:

CN 21: PN: WO03020884 SEQID: 21 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 2 a 4 c 12 g 2 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference

Not Given|WO2003020884
|unclaimed
|SEQID 21

SEQ 1 ggtgcgtcga cgcagggggg

HITS AT: 3-20

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS
DT.CA Caplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 61 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 501834-16-8 REGISTRY
CN DNA, d(N-N-T-G-C-G-C-G-C-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 8: PN: WO03020884 SEQID: 8 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 1 a 5 c 11 g 1 t 2 n

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003020884
	unclaimed
	SEQID 8

SEQ 1 nntgcgccgg cgcagggggg

HITS AT: 3-20

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS
DT.CA Caplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 62 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 501834-15-7 REGISTRY
CN DNA, d(N-N-T-G-C-G-T-C-G-A-C-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 7: PN: WO03020884 SEQID: 7 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 2 a 4 c 10 g 2 t 2 n

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
----------	--------

Source	Reference
Not Given	WO2003020884 unclaimed SEQID 7

SEQ 1 nntgcgtcga cgcagggggg
=====

HITS AT: 3-20

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS
DT.CA Caplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 63 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 501834-14-6 REGISTRY
CN DNA, d(N-N-T-G-C-A-C-C-G-G-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6: PN: WO03020884 SEQID: 6 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 2 a 4 c 10 g 2 t 2 n

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2003020884 unclaimed SEQID 6

SEQ 1 nntgcaccgg tgcagggggg
=====

HITS AT: 3-20

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS
DT.CA Caplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 64 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 501834-13-5 REGISTRY
CN DNA, d(N-N-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5: PN: WO03020884 SEQID: 5 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 3 a 3 c 9 g 3 t 2 n

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
=====	
Not Given	WO2003020884
	unclaimed
	SEQID 5

SEQ 1 nntgcatcga tgcagggggg

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Cplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 65 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 501729-68-6 REGISTRY
 CN DNA, d(G-G-T-G-C-A-C-C-G-G-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 2: PN: WO03020884 SEQID: 2 claimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 2 a 4 c 12 g 2 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
=====	
Not Given	WO2003020884
	claimed
	SEQID 2

SEQ 1 ggtgcaccgg tgcagggggg

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Cplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES
 (Uses)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 66 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 501729-67-5 REGISTRY
 CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 1: PN: WO03020884 SEQID: 1 claimed DNA
 FS NUCLEIC ACID SEQUENCE

SQL 20
NA 3 a 3 c 11 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
=====	
Not Given	WO2003020884
	claimed
	SEQID 1

SEQ 1 ggtgcatcga tgcagggggg
=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES
(Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 67 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 500239-90-7 REGISTRY
CN DNA, d(G-G-G-G-T-C-G-A-C-G-T-C-G-A-C-G-T-C-G-A-G-G-G-G-G-G) (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN 55: PN: WO03015711 SEQID: 56 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 27
NA 3 a 5 c 16 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
=====	
Not Given	WO2003015711
	unclaimed
	SEQID 56

SEQ 1 ggggtcgacg tcgacgtcga gggggggg
=====

HITS AT: 1-27

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 68 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 482663-89-8 REGISTRY

CN DNA, d(G-sp-G[oxy(mercaptophosphinylidene)oxy-1,3-propanediyl oxyphosphinicooxy]T-C-G-T-G-C[oxyphosphinicooxy-1,3-propanediyl oxyphosphinicooxy]A-T-C-G-A-T[oxyphosphinicooxy-1,3-propanediyl oxyphosphinicooxy]G-C-A-C-G-A[oxyphosphinicooxy-1,3-propanediyl oxyphosphinicooxy]G-G-sp-G-sp-G-sp-G-sp-G) (9CI) (CA INDEX NAME)

FS NUCLEIC ACID SEQUENCE

SQL 26

NA 4 a 5 c 13 g 4 t

NTE modified

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-22 - g-23	P-thio
modified link	g-23 - g-24	P-thio
modified link	g-24 - g-25	P-thio
modified link	g-25 - g-26	P-thio
uncommon link	g-2 - t-3	unavailable
uncommon link	c-8 - a-9	unavailable
uncommon link	t-14 - g-15	unavailable
uncommon link	a-20 - g-21	unavailable

SEQ 1 ggtcgtgcat cgatgcacga gggggg

=====

HITS AT: 6-26

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 69 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 482663-88-7 REGISTRY

CN DNA, d(G-sp-G[oxy(mercaptophosphinylidene)oxy-1,3-propanediyl oxyphosphinicooxy]T-G-C[oxyphosphinicooxy-1,3-propanediyl oxyphosphinicooxy]A-T-C-G-A-T[oxyphosphinicooxy-1,3-propanediyl oxyphosphinicooxy]G-C-A[oxyphosphinicooxy-1,3-propanediyl oxyphosphinicooxy]G-G-sp-G-sp-G-sp-G-sp-G) (9CI) (CA INDEX NAME)

FS NUCLEIC ACID SEQUENCE

SQL 20

NA 3 a 3 c 11 g 3 t

NTE modified

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-16 - g-17	P-thio
modified link	g-17 - g-18	P-thio
modified link	g-18 - g-19	P-thio
modified link	g-19 - g-20	P-thio
uncommon link	g-2 - t-3	unavailable
uncommon link	c-5 - a-6	unavailable
uncommon link	t-11 - g-12	unavailable

uncommon link a-14 - g-15 unavailable

SEQ 1 ggtgcatcga tgcagggggg

=====

HITS AT: 3-20

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 70 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 459471-17-1 REGISTRY

CN DNA, d(G-sp-G-sp-T-G-C-A-T-C-G-A-T-G-C-A-G-sp-G-sp-G-sp-G-sp-G) (9CI)
(CA INDEX NAME)

FS NUCLEIC ACID SEQUENCE

SQL 20

NA 3 a 3 c 11 g 3 t

NTE modified

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-2 - t-3	P-thio
modified link	g-15 - g-16	P-thio
modified link	g-16 - g-17	P-thio
modified link	g-17 - g-18	P-thio
modified link	g-18 - g-19	P-thio
modified link	g-19 - g-20	P-thio

SEQ 1 ggtgcatcga tgcagggggg

=====

HITS AT: 3-20

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS

DT.CA Caplus document type: Journal

RL.NP Roles from non-patents: BIOL (Biological study); PRP (Properties)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 71 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 459471-16-0 REGISTRY

CN DNA, d(G-sp-G-sp-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-sp-G-sp-G) (9CI) (CA INDEX NAME)

FS NUCLEIC ACID SEQUENCE

SQL 20

NA 3 a 3 c 11 g 3 t

NTE modified

type	location	description
------	----------	-------------

```
-----
modified link   g-1       - g-2       P-thio
modified link   g-2       - t-3       P-thio
modified link   g-18      - g-19      P-thio
modified link   g-19      - g-20      P-thio
-----
```

SEQ 1 ggtgcatcga tgcagggggg

=====

HITS AT: 3-20

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS

DT.CA Cplus document type: Journal

RL.NP Roles from non-patents: BIOL (Biological study); PRP (Properties)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 72 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 441364-86-9 REGISTRY

CN DNA, d(G-G-G-G-T-C-G-A-C-G-T-C-G-A-C-G-T-C-G-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 653: PN: WO02053141 SEQID: 1077 claimed DNA

FS NUCLEIC ACID SEQUENCE

SQL 27

NA 3 a 5 c 16 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2002053141
	claimed
	SEQID 1077

SEQ 1 ggggtcgacg tcgacgtcga gggggggg

=====

HITS AT: 1-27

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Cplus document type: Patent

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 73 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 434529-77-8 REGISTRY

CN DNA, d(G-sp-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-sp-G) (9CI) (CA INDEX NAME)

FS NUCLEIC ACID SEQUENCE

SQL 20

NA 3 a 3 c 11 g 3 t
NTE modified

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-19 - g-20	P-thio

SEQ 1 ggtgcatcga tgcagggggg

=====

HITS AT: 3-20

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA Caplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 74 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 406966-35-6 REGISTRY
CN DNA, d(G-sp-G-sp-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-sp-G-sp-G) (9CI) (CA INDEX NAME)
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 3 a 3 c 11 g 3 t
NTE modified

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-2 - t-3	P-thio
modified link	g-18 - g-19	P-thio
modified link	g-19 - g-20	P-thio

SEQ 1 ggtgcatcga tgcagggggg

=====

HITS AT: 3-20

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS
DT.CA Caplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 75 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 406966-34-5 REGISTRY
CN DNA, d(G-sp-G-sp-T-G-C-A-C-C-G-G-T-G-C-A-G-G-sp-G-sp-G-sp-G-sp-G) (9CI) (CA INDEX NAME)
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 2 a 4 c 12 g 2 t

NTE modified

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-2 - t-3	P-thio
modified link	g-16 - g-17	P-thio
modified link	g-17 - g-18	P-thio
modified link	g-18 - g-19	P-thio
modified link	g-19 - g-20	P-thio

SEQ 1 ggtgcaccgg tgcagggggg

=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS

DT.CA Cplus document type: Journal

RL.NP Roles from non-patents: BIOL (Biological study); PRP (Properties); USES (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 76 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 400186-59-6 REGISTRY

CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 71: PN: WO0211761 PAGE: 8 claimed sequence

FS NUCLEIC ACID SEQUENCE

SQL 19

NA 3 a 3 c 10 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence | Patent

Source | Reference

=====+=====

Not Given | WO2002011761

| claimed PAGE

| 8

SEQ 1 ggtgcatcga tgcagggggg

=====

HITS AT: 3-19

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS

DT.CA Cplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 77 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 400186-49-4 REGISTRY

CN DNA, d(G-G-T-G-C-A-C-C-G-G-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 60: PN: WO0211761 PAGE: 8 claimed sequence

FS NUCLEIC ACID SEQUENCE

SQL 20

NA 2 a 4 c 12 g 2 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2002011761
	claimed PAGE
	8

SEQ 1 ggtgcaccgg tgcagggggg

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS

DT.CA CAPLUS document type: Patent

RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 78 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 400186-47-2 REGISTRY

CN DNA, d(G-G-T-G-C-G-T-C-G-A-C-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 57: PN: WO0211761 PAGE: 8 claimed sequence

FS NUCLEIC ACID SEQUENCE

SQL 20

NA 2 a 4 c 12 g 2 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2002011761
	claimed PAGE
	8

SEQ 1 ggtgcgtcga cgcagggggg

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS

DT.CA CAPLUS document type: Patent

RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 79 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 400186-43-8 REGISTRY
 CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 50: PN: WO0211761 PAGE: 8 claimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 3 c 11 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2002011761 claimed PAGE 8

SEQ 1 ggtgcatcga tgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES
 (Uses)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 80 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 381261-19-4 REGISTRY
 CN DNA, d(U-A-U-A-U-A-U-C-C-C-C-C-C-G-G-T-G-C-A-C-C-G-G-T-G-C-A-G-G-G-G-G-A-U-A-U-A-U-A) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 522: PN: WO0193902 SEQID: 548 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 40
 NA 9 a 10 c 12 g 2 t 7 u

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2001093902 unclaimed SEQID 548

SEQ 1 uauauauccc cccggtgcac cgggtgcagg gggauauaua
 =====

HITS AT: 16-33

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 DT.CA Caplus document type: Patent

RL.P Roles from patents: PRP (Properties)

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 81 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 381261-17-2 REGISTRY
CN DNA, d(A-A-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 520: PN: WO0193902 SEQID: 546 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 5 a 3 c 9 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference

Not Given	WO2001093902 unclaimed SEQID 546
-----------	--

SEQ 1 aatgcatcga tgcagggggg

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: PRP (Properties)

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 82 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 381261-08-1 REGISTRY
CN DNA, d(U-C-A-A-C-G-U-U-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 510: PN: WO0193902 SEQID: 536 unclaimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 26
NA 5 a 5 c 10 g 3 t 3 u

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference

Not Given	WO2001093902 unclaimed SEQID 536
-----------	--

SEQ 1 ucaacguutg catcgatgca gggggg

HITS AT: 9-26

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 83 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 381261-07-0 REGISTRY
 CN DNA, d(U-C-A-A-C-G-U-U-A-A-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G) (9CI) (CA
 INDEX NAME)
 OTHER NAMES:
 CN 509: PN: WO0193902 SEQID: 535 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 28
 NA 7 a 5 c 10 g 3 t 3 u

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2001093902
	unclaimed
	SEQID 535

SEQ 1 ucaacguuaa tgcacgatg cagggggg
 =====

HITS AT: 11-28

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 84 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 381261-06-9 REGISTRY
 CN DNA, d(U-C-A-A-C-G-U-U-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX
 NAME)

OTHER NAMES:

CN 508: PN: WO0193902 SEQID: 534 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 25
 NA 5 a 5 c 9 g 3 t 3 u

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2001093902
	unclaimed
	SEQID 534

SEQ 1 ucaacguutg catcgatgca gggggg
 == =====

HITS AT: 9-25

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: PRP (Properties)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 85 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 381261-05-8 REGISTRY

CN DNA, d(U-C-A-A-C-G-U-U-G-G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI)
(CA INDEX NAME)

OTHER NAMES:

CN 507: PN: WO0193902 SEQID: 533 unclaimed DNA

FS NUCLEIC ACID SEQUENCE

SQL 29

NA 5 a 5 c 13 g 3 t 3 u

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2001093902
	unclaimed
	SEQID 533

=====+=====

Not Given|WO2001093902
unclaimed
SEQID 533

SEQ 1 ucaacguugg gtgcacgat gcagggggg

=====

HITS AT: 12-29

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: PRP (Properties)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 86 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 381261-01-4 REGISTRY

CN DNA, d(U-C-A-A-C-G-U-U-G-G-T-G-C-A-C-C-G-G-T-G-C-A-G-G-G-G-G-G) (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN 503: PN: WO0193902 SEQID: 529 unclaimed DNA

FS NUCLEIC ACID SEQUENCE

SQL 28

NA 4 a 6 c 13 g 2 t 3 u

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2001093902
	unclaimed
	SEQID 529

=====+=====

Not Given|WO2001093902
unclaimed
SEQID 529

SEQ 1 ucaacguugg tgcaccggtg cagggggg

=====

HITS AT: 11-28

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 87 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 381260-99-7 REGISTRY
 CN DNA, d(U-C-A-A-C-G-U-U-G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 501: PN: WO0193902 SEQID: 527 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 28
 NA 5 a 5 c 12 g 3 t 3 u

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2001093902
	unclaimed
	SEQID 527

SEQ 1 ucaacguugg tgcacgatg cagggggg
 =====

HITS AT: 11-28
 MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 88 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 381260-42-0 REGISTRY
 CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G-U-C-G-A-G-C-G-U-U-C-U-C) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 437: PN: WO0193902 SEQID: 463 unclaimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 32
 NA 4 a 7 c 14 g 3 t 4 u

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2001093902
	unclaimed
	SEQID 463

SEQ 1 ggtgcatcga tgcagggggg ucgagcguuc uc
 =====

HITS AT: 3-20
 MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

DT.CA Caplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 89 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 366065-16-9 REGISTRY
 CN DNA, d(G-sp-G-sp-T-G-C-A-T-C-G-A-T-G-C-A-G-sp-G-sp-G-sp-G-sp-G) (9CI)
 (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 3 c 11 g 3 t
 NTE modified

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-2 - t-3	P-thio
modified link	g-16 - g-17	P-thio
modified link	g-17 - g-18	P-thio
modified link	g-18 - g-19	P-thio
modified link	g-19 - g-20	P-thio

SEQ 1 ggtgcatcga tgcagggggg
 =====
 HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study); PRP (Properties); USES
 (Uses)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 90 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 350271-18-0 REGISTRY
 CN DNA, d(G-sp-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-sp-G) (9CI) (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 19
 NA 3 a 3 c 10 g 3 t
 NTE

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-18 - g-19	P-thio

SEQ 1 ggtgcatcga tgcagggggg
 =====
 HITS AT: 3-19

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 91 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 350271-08-8 REGISTRY
 CN DNA, d(G-sp-G-T-G-C-A-C-C-G-G-T-G-C-A-G-G-G-G-G-sp-G) (9CI) (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 2 a 4 c 12 g 2 t
 NTE

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-19 - g-20	P-thio

SEQ 1 ggtgcaccgg tgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 92 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 350271-06-6 REGISTRY
 CN DNA, d(G-sp-G-T-G-C-G-T-C-G-A-C-G-C-A-G-G-G-G-G-sp-G) (9CI) (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 2 a 4 c 12 g 2 t
 NTE

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-19 - g-20	P-thio

SEQ 1 ggtgcgtcga cgcagggggg
 =====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES

(Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 93 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 350271-02-2 REGISTRY
CN DNA, d(G-sp-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-sp-G) (9CI) (CA INDEX NAME)
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 3 a 3 c 11 g 3 t
NTE

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-19 - g-20	P-thio

SEQ 1 ggtgcatcga tgcagggggg
=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 94 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 350270-01-8 REGISTRY
CN DNA, d(C-T-C-G-T-C-G-A-C-G-A-G-C-G-G-G-G-T-T-G-A-T-G-G-A-C-C-G-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 10: PN: WO0149845 PAGE: 26 unclaimed sequence
FS NUCLEIC ACID SEQUENCE
SQL 29
NA 4 a 7 c 13 g 5 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2001049845
	unclaimed
	PAGE 26

SEQ 1 ctcgtcgacg agcgggggttg atggaccgg
=====

HITS AT: 1-17

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Patent
RL.P Roles from patents: PRP (Properties)

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 95 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 334074-92-9 REGISTRY
CN DNA, d(G-sp-G-sp-T-G-C-A-C-C-G-G-T-G-C-A-G-G-sp-G-sp-G-sp-G) (9CI)
(CA INDEX NAME)
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 2 a 4 c 12 g 2 t
NTE

type	location		description
modified link	g-1	- g-2	P-thio
modified link	g-2	- t-3	P-thio
modified link	g-16	- g-17	P-thio
modified link	g-17	- g-18	P-thio
modified link	g-18	- g-19	P-thio
modified link	g-19	- g-20	P-thio

SEQ 1 ggtgcaccgg tgcagggggg
=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS
DT.CA Caplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 96 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 334074-91-8 REGISTRY
CN DNA, d(G-sp-G-sp-T-G-C-A-T-C-G-A-T-G-C-A-G-G-sp-G-sp-G-sp-G) (9CI)
(CA INDEX NAME)
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 3 a 3 c 11 g 3 t
NTE

type	location		description
modified link	g-1	- g-2	P-thio
modified link	g-2	- t-3	P-thio
modified link	g-16	- g-17	P-thio
modified link	g-17	- g-18	P-thio
modified link	g-18	- g-19	P-thio
modified link	g-19	- g-20	P-thio

SEQ 1 ggtgcacgcga tgcagggggg
=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
CI MAN

SR CA
 LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 97 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 332956-63-5 REGISTRY
 CN DNA, d(G-sp-G-sp-G-G-T-C-G-A-C-G-T-C-G-A-C-G-T-C-G-A-G-G-sp-G-sp-G-sp-G-sp-G-sp-G) (9CI) (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 27
 NA 3 a 5 c 16 g 3 t
 NTE

type	location	description
modified link	g-1 - g-2	P-thio
modified link	g-22 - g-23	P-thio
modified link	g-23 - g-24	P-thio
modified link	g-24 - g-25	P-thio
modified link	g-25 - g-26	P-thio

SEQ 1 ggggtcgacg tcgacgtcga gggggggg
 =====
 HITS AT: 1-27

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES
 (Uses)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 98 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 331880-34-3 REGISTRY
 CN DNA, d(G-G-G-G-T-C-G-A-C-G-T-C-G-A-C-G-T-C-G-A-G-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 1083: PN: WO0122972 SEQID: 1077 claimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 27
 NA 3 a 5 c 16 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Artificial	WO2001022972
sequence	claimed
	SEQID 1077

SEQ 1 ggggtcgacg tcgacgtcga gggggggg
 =====
 HITS AT: 1-27

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 99 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 302865-85-6 REGISTRY
 CN DNA, d(G-G-T-G-G-A-T-C-G-A-T-C-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 37: PN: WO0061151 SEQID: 137 claimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 3 a 3 c 11 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Synthetic	WO2000061151 claimed SEQID 137

SEQ 1 ggtggatcga tccagggggg
 =====
 HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER
 DT.CA Caplus document type: Patent
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PRP (Properties); USES (Uses)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 100 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 302865-84-5 REGISTRY
 CN DNA, d(G-G-T-A-T-A-T-C-G-A-T-A-T-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 36: PN: WO0061151 SEQID: 136 claimed DNA
 FS NUCLEIC ACID SEQUENCE
 SQL 20
 NA 5 a 1 c 9 g 5 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Synthetic	WO2000061151 claimed SEQID 136

SEQ 1 ggtatatcga tatagggggg

=====

HITS AT: 3-20

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

DT.CA Caplus document type: Patent

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 101 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 301939-75-3 REGISTRY

CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 54: PN: WO0061151 SEQID: 53 claimed DNA

FS NUCLEIC ACID SEQUENCE

SQL 19

NA 3 a 3 c 10 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
-----+-----	
Synthetic	WO2000061151
	claimed
	SEQID 53
-----+-----	
	WO2000061151
	claimed
	SEQID 73

SEQ 1 ggtgcatcga tgcagggggg

=====

HITS AT: 3-19

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

DT.CA Caplus document type: Patent

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 102 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 301939-65-1 REGISTRY

CN DNA, d(G-G-T-G-C-A-C-C-G-G-T-G-C-A-G-G-G-G-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 43: PN: WO0061151 SEQID: 42 claimed DNA

FS NUCLEIC ACID SEQUENCE

SQL 20
NA 2 a 4 c 12 g 2 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
=====+=====	
Synthetic	WO2000061151
	claimed
	SEQID 42

SEQ 1 ggtgcaccgg tgcagggggg
=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Patent
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 103 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 301939-63-9 REGISTRY
CN DNA, d(G-G-T-G-C-G-T-C-G-A-C-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 39: PN: WO0061151 SEQID: 39 claimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 2 a 4 c 12 g 2 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
=====+=====	
Synthetic	WO2000061151
	claimed
	SEQID 39
-----+-----	
	WO2000061151
	claimed
	SEQID 41

SEQ 1 ggtgcgctga cgcagggggg
=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Patent
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 104 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 301939-59-3 REGISTRY
CN DNA, d(G-G-T-G-C-A-T-C-G-A-T-G-C-A-G-G-G-G-G-G) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 32: PN: WO0061151 SEQID: 32 claimed DNA
FS NUCLEIC ACID SEQUENCE
SQL 20
NA 3 a 3 c 11 g 3 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
=====+=====	
Synthetic	WO2000061151
	claimed
	SEQID 32
-----+-----	
	WO2000061151
	claimed
	SEQID 34
-----+-----	
	WO2000061151
	claimed
	SEQID 37
-----+-----	
	WO2000061151
	claimed
	SEQID 38
-----+-----	
	WO2000061151
	claimed
	SEQID 43
-----+-----	
	WO2000061151
	claimed
	SEQID 72

SEQ 1 ggtgcatcga tgcagggggg
=====

HITS AT: 3-20

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA Caplus document type: Patent
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 105 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN
RN 115013-83-7 REGISTRY
CN Deoxyribonucleic acid, d(G-G-G-A-T-C-G-A-T-C-C-C-C-A-A-T-T-T-G-A),
5'-(dihydrogen phosphate), homopolymer, complex with deoxyribonucleic acid

d(T-C-A-A-A-T-T-G-G-G-G-G-A-T-C-G-A-T-C-C-C) 5'-(dihydrogen phosphate)
homopolymer (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN DNA, d(T-C-A-A-A-T-T-G-G-G-G-G-A-T-C-G-A-T-C-C-C), 5'-(dihydrogen phosphate), homopolymer, complex with DNA d(G-G-G-A-T-C-G-A-T-C-C-C-C-A-A-T-T-T-G-A) 5'-(dihydrogen phosphate) homopolymer (1:1) (9CI)

FS NUCLEIC ACID SEQUENCE

SQL 42,21,21

NA 10 a 11 c 11 g 10 t

NTE doublestranded (2)
modified

type	location	description
modified base	g-1	5'-phosphate
modified base	t-1[2]	5'-phosphate
homopolymer	?	unavailable
homopolymer	?[2]	unavailable

SEQ 1 gggatcgatc cccaatttg a

SEQ 1 tcaaattggg ggatcgatcc c

=====

HITS AT: 1-12, 10-21

MF (C205 H259 N80 O127 P21)x . (C204 H259 N78 O127 P21)x

PCT Manual registration

SR CA

LC STN Files: CA, CAPLUS

DT.CA CAplus document type: Journal

RL.NP Roles from non-patents: BIOL (Biological study)

CM 1

CRN 115013-82-6

CMF (C204 H259 N78 O127 P21)x

CCI PMS

CM 2

CRN 114949-62-1

CMF C204 H259 N78 O127 P21

CCI MAN

CM 3

CRN 115013-81-5

CMF (C205 H259 N80 O127 P21)x

CCI PMS

CM 4

CRN 114949-64-3

CMF C205 H259 N80 O127 P21

CCI MAN

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 106 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 115013-81-5 REGISTRY

CN DNA, d(T-C-A-A-A-T-T-G-G-G-G-G-A-T-C-G-A-T-C-C-C), 5'-(dihydrogen phosphate), homopolymer (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Deoxyribonucleic acid, d(T-C-A-A-A-T-T-G-G-G-G-A-T-C-G-A-T-C-C-C),
5'-(dihydrogen phosphate), homopolymer
FS NUCLEIC ACID SEQUENCE
SQL 21
NA 5 a 5 c 6 g 5 t
NTE

type	location	description
modified base	t-1	5'-phosphate
homopolymer	?	unavailable

SEQ 1 tcaaattggg ggategatcc c
=====

HITS AT: 1-12, 10-21

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF (C205 H259 N80 O127 P21)x
CI PMS, COM
PCT Manual registration
SR CA

CM 1

CRN 114949-64-3
CMF C205 H259 N80 O127 P21
CCI MAN

L17 ANSWER 107 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 115013-80-4 REGISTRY

CN Deoxyribonucleic acid, d(G-G-G-A-T-C-G-A-T-C-C-C-C-A-G-C-T-C-G-A),
5'-(dihydrogen phosphate), homopolymer, complex with deoxyribonucleic acid
d(T-C-G-A-G-C-T-G-G-G-G-A-T-C-G-A-T-C-C-C) 5'-(dihydrogen phosphate)
homopolymer (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN DNA, d(T-C-G-A-G-C-T-G-G-G-G-A-T-C-G-A-T-C-C-C), 5'-(dihydrogen
phosphate), homopolymer, complex with DNA d(G-G-G-A-T-C-G-A-T-C-C-C-C-A-
G-C-T-C-G-A) 5'-(dihydrogen phosphate) homopolymer (1:1) (9CI)
FS NUCLEIC ACID SEQUENCE
SQL 42,21,21
NA 7 a 14 c 14 g 7 t
NTE doublestranded (2)
modified

type	location	description
modified base	g-1	5'-phosphate
modified base	t-1[2]	5'-phosphate
homopolymer	?	unavailable
homopolymer	?[2]	unavailable

SEQ 1 gggatcgatc cccagctcg a

SEQ 1 tcgagctggg ggategatcc c
=====

HITS AT: 1-12, 10-21

MF (C204 H258 N81 O128 P21)x . (C202 H257 N80 O126 P21)x
PCT Manual registration
SR CA

LC STN Files: CA, CAPLUS
 DT.CA Caplus document type: Journal
 RL.NP Roles from non-patents: BIOL (Biological study)

CM 1

CRN 115013-79-1
 CMF (C202 H257 N80 O126 P21)x
 CCI PMS

CM 2

CRN 114949-60-9
 CMF C202 H257 N80 O126 P21
 CCI MAN

CM 3

CRN 115013-78-0
 CMF (C204 H258 N81 O128 P21)x
 CCI PMS

CM 4

CRN 114949-61-0
 CMF C204 H258 N81 O128 P21
 CCI MAN
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 108 OF 108 REGISTRY COPYRIGHT 2004 ACS on STN

RN 115013-78-0 REGISTRY

CN DNA, d(T-C-G-A-G-C-T-G-G-G-G-A-T-C-G-A-T-C-C-C), 5'-(dihydrogen phosphate), homopolymer (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Deoxyribonucleic acid, d(T-C-G-A-G-C-T-G-G-G-G-A-T-C-G-A-T-C-C-C), 5'-(dihydrogen phosphate), homopolymer

FS NUCLEIC ACID SEQUENCE

SQL 21

NA 3 a 6 c 8 g 4 t

NTE

type	location	description
modified base	t-1	5'-phosphate
homopolymer	?	unavailable

SEQ 1 tcgagctggg ggatcgatcc c
 =====

HITS AT: 1-12, 10-21

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF (C204 H258 N81 O128 P21)x

CI PMS, COM

PCT Manual registration

SR CA

CM 1

CRN 114949-61-0
 CMF C204 H258 N81 O128 P21

CCI MAN

=> fil capl uspatf toxcenter; s 117

FILE 'CAPLUS' ENTERED AT 14:55:40 ON 01 JUL 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 14:55:40 ON 01 JUL 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 14:55:40 ON 01 JUL 2004

COPYRIGHT (C) 2004 ACS

L18 57 L17

=> dup rem l18

PROCESSING COMPLETED FOR L18

L19 37 DUP REM L18 (20 DUPLICATES REMOVED)

ANSWERS '1-31' FROM FILE CAPLUS

ANSWERS '32-37' FROM FILE USPATFULL

=> d ibib ed ab hitrn 1-37; fil hom

L19 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2003:417589 CAPLUS

DOCUMENT NUMBER: 139:5654

TITLE: TLR7 knockout nonhuman animal for screening synthetic immunopotentiator

INVENTOR(S): Akira, Shizuo; Tomizawa, Hideyuki; Yamaoka, Takashi

PATENT ASSIGNEE(S): Japan Science and Technology Corporation, Japan;

Sumitomo Pharmaceuticals Company, Limited

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003043588	A1	20030530	WO 2002-JP12234	20021122

W: CA, JP, US

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,

LU, MC, NL, PT, SE, SK, TR

PRIORITY APPLN. INFO.: JP 2001-358295 A 20011122

ED Entered STN: 01 Jun 2003

AB It is intended to provide a nonhuman model animal unresponsive to a synthetic compd. which lacks a gene function encoding TLR7 recognizing an immunopotentiating synthetic compd. such as imidazoquinoline on its chromosome. A gene fragment of the whole gene sites including the intracellular domain and the transmembrane domain or a part thereof of a TLR7 gene obtained from a mouse gene library is substituted by a plasmid having poly(A) signal and a marker gene to construct a targeting vector. Then this targeting vector is linearized and transferred into embryo stem cells. The target embryo stem cells lacking the TLR7 gene function are microinjected into a mouse blastocyst to construct a chimeric mouse. Then this chimeric mouse is crossed with a wild type mouse to give a heterozygote mouse. Next, the heterozygote mouse is intercrossed and thus a TLR7 knockout mouse is obtained. The TLR7 knockout mice are useful for

screening substance that is capable of inhibiting or promoting immunopotential activity of synthetic imidazoquinoline compds. such as Imiquimod and R-848.

IT 534784-78-6 use Registry # to match citation to sequence

RL: PRP (Properties)

(unclaimed nucleotide sequence; tLR7 knockout nonhuman animal for screening synthetic immunopotentiator)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2003:377001 CAPLUS

DOCUMENT NUMBER: 138:390866

TITLE: Use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo

INVENTOR(S): Klinman, Dennis M.; Gursel, Ihsan; Ishii, Ken J.; Kawakami, Koji; Joshi, Bharat H.; Puri, Raj K.

PATENT ASSIGNEE(S): Department of Health and Human Services, USA

SOURCE: PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040308	A2	20030515	WO 2002-US24235	20020729
WO 2003040308	A3	20031120		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-308283P P 20010727
US 2002-206407 A 20020725

OTHER SOURCE(S): MARPAT 138:390866

ED Entered STN: 16 May 2003

AB Sterically stabilized cationic liposomes (SSCL) encapsulating a K type oligodeoxynucleotide (ODN) including a CpG motif are disclosed. These SSCL encapsulating a K type ODN can be used to effectively deliver the ODN to a cell. A novel method is also disclosed for producing the SSCL encapsulating the K type ODN. Administration of the SSCL encapsulating a K type ODN and a chemotherapeutic agent, such as a chimeric mol. comprising a targeting mol. selected from the group consisting of an IL-13, and an anti-IL-13 receptor antibody; and an effector mol. selected from the group consisting of a Pseudomonas exotoxin, a Diphtheria toxin, and a radionuclide, can be used to dramatically reduce the growth of solid tumors.

IT 524985-88-4 524985-91-9 524985-93-1
524985-98-6 524985-99-7 524986-00-3
524986-11-6 524986-12-7

RL: PRP (Properties)

(unclaimed nucleotide sequence; use of sterically stabilized cationic liposomes to efficiently deliver CpG oligonucleotides in vivo)

L19 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3
 ACCESSION NUMBER: 2003:154198 CAPLUS
 DOCUMENT NUMBER: 138:203655
 TITLE: Oligonucleotides containing stimulatory
 phosphorothioate motif and neutralizing motif for
 treating infections, allergies and cancers
 INVENTOR(S): Krieg, Arthur M.; Vollmer, Jorg; Uhlman, Eugen
 PATENT ASSIGNEE(S): Coley Pharmaceutical Group, Inc., USA; Coley
 Pharmaceutical G.m.b.H.; University of Iowa Research
 Foundation
 SOURCE: PCT Int. Appl., 115 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015711	A2	20030227	WO 2002-US26468	20020819
WO 2003015711	C2	20030410		
WO 2003015711	A3	20040610		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG

US 2003148976 A1 20030807 US 2002-224523 20020819
 PRIORITY APPLN. INFO.: US 2001-313273P P 20010817
 US 2002-393952P P 20020703

ED Entered STN: 28 Feb 2003
 AB A class of immunostimulatory nucleic acids having at least two
 functionally and structurally defined domains is provided. The nucleic
 acids or oligodeoxynucleotides contg. a combination of a stimulating motif
 (i.e. CpG) and a neutralizing motif (i.e. CG-rich palindrome or CG
 repeats) are, surprisingly, highly immunostimulatory. This class of
 combination motif immunostimulatory nucleic acids characteristically
 activate B cells and NK cells, and also induce prodn. of type I
 interferon. The immunostimulatory nucleic acids or oligonucleotides are
 therefore, useful for treating a variety of immune related disorders such
 as cancer, infectious disease, and allergic disorders.
 IT 500239-90-7
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; oligonucleotides contg. stimulatory
 phosphorothioate motif and neutralizing motif for treating infections,
 allergies and cancers)

L19 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 4
 ACCESSION NUMBER: 2003:6160 CAPLUS
 DOCUMENT NUMBER: 138:88635
 TITLE: Chimeric immunomodulatory compounds comprising nucleic
 acids linked through dendrimer or polysaccharide
 spacer and antigen for treating allergy, infection or
 cancer
 INVENTOR(S): Fearon, Karen L.; Dina, Dino; Tuck, Stephen F.
 PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA
 SOURCE: PCT Int. Appl., 224 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000922	A2	20030103	WO 2002-US20025	20020621
WO 2003000922	A3	20031023		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1404873	A2	20040407	EP 2002-744589	20020621
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2001-299883P	P 20010621
			US 2002-375253P	P 20020423
			WO 2002-US20025	W 20020621

ED Entered STN: 05 Jan 2003

AB The invention provides immunomodulatory compds. (CIC) and methods for immunomodulation of individuals using the immunomodulatory compds. The CIC comprises one or more nucleic acid moieties and one or more non-nucleic acid moieties such as dendrimer, polysaccharide, and crosslinked polysaccharide through phosphodiester, phosphorothioate ester, phosphorodithioate ester, and other linkages. The CIC is capable of stimulating prodn. of interferon .gamma. and .alpha. by human peripheral blood mononuclear cells, as well as human B cell proliferation. Endotoxin-free compns. comprising the CIC covalently or non-covalently conjugated with antigen and cationic microsphere are useful for treating disorders assocd. with IgE or Th2-type immune response such as allergy, asthma, infection, viral infection, idiopathic pulmonary fibrosis, and cancer.

IT 482663-88-7P 482663-89-8P

RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(chimeric immunomodulatory compds. comprising nucleic acids linked through dendrimer or polysaccharide spacer and antigen for treating allergy, infection or cancer)

L19 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 5

ACCESSION NUMBER: 2003:950038 CAPLUS
DOCUMENT NUMBER: 140:26897
TITLE: Chimeric immunomodulatory compounds comprising two or more nucleic acid moieties and non-nucleic acid spacer
INVENTOR(S): Fearon, Karen L.; Dina, Dino; Tuck, Stephen F.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 96 pp., Cont.-in-part of U.S. Ser. No. 176,883.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003225016	A1	20031204	US 2002-328578	20021223
US 2003175731	A1	20030918	US 2002-176883	20020621
US 2003199466	A1	20031023	US 2002-177826	20020621

PRIORITY APPLN. INFO.:

US 2001-299883P	P	20010621
US 2002-375253P	P	20020423
US 2002-176883	A2	20020621
US 2002-177826	A2	20020621

ED Entered STN: 05 Dec 2003

AB The invention provides immunomodulatory compds. and methods for immunomodulation of individuals using the immunomodulatory compds. The immunomodulatory compds. comprise two or more nucleic acid moieties and a non-nucleic acid spacer moiety. The nucleic acid contains e.g. 5'-CG-3', 5'-TCG-3', 5'-TCGA-3', 5'-TCGACGT-3', or 5'-TCGACGA-3'; and the non-nucleic acid is an oligoethylene glycol such as hexaethylene glycol. The chimeric compds. are incorporated into endotoxin-free compns. comprising antigen, pharmaceutically acceptable excipient, and optionally a cationic microsphere for modulating immune response.

IT 631926-11-9P 631926-12-0P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(chimeric immunomodulatory compds. comprising two or more nucleic acid moieties and non-nucleic acid spacer)

L19 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 2003:590824 CAPLUS

DOCUMENT NUMBER: 139:154891

TITLE: Multiple CpG oligodeoxynucleotides and their use to induce an immune response

INVENTOR(S): Klinman, Dennis; Ishii, Ken; Verthelyi, Daniela

PATENT ASSIGNEE(S): The Government of the U.S.A., the Secretary of the Department of Health and Human Services, USA

SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of Appl. No. PCT/US01/01122.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003144229	A1	20030731	US 2002-194035	20020712
WO 2001051500	A1	20010719	WO 2001-US1122	20010112

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2000-176115P	P	20000114
WO 2001-US1122	A2	20010112

OTHER SOURCE(S): MARPAT 139:154891

ED Entered STN: 01 Aug 2003

AB Compns. including multiple oligodeoxynucleotides with a CpG motif are disclosed herein. The compns. can include either D or K type oligodeoxynucleotides. These compns. are of use in inducing an immune

response in a large percentage of the individuals in a population.
 IT 569431-10-3 569431-14-7 569431-16-9
 569431-26-1
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; multiple CpG oligodeoxynucleotides and
 their use to induce an immune response)

L19 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 7
 ACCESSION NUMBER: 2003:355834 CAPLUS
 DOCUMENT NUMBER: 138:362665
 TITLE: Immunostimulatory nucleic acids for the treatment of
 asthma and allergy
 INVENTOR(S): Bratzler, Robert L.; Petersen, Deanna M.; Fouron, Yves
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 221 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003087848	A1	20030508	US 2001-776479	20010202
US 2004067902	A9	20040408		

PRIORITY APPLN. INFO.: US 2000-179991P P 20000203

OTHER SOURCE(S): MARPAT 138:362665

ED Entered STN: 09 May 2003

AB The invention involves administration of an immunostimulatory nucleic acid
 alone or in combination with an asthma/allergy medicament for the
 treatment or prevention of asthma and allergy in subjects. The
 combination of drugs are administered in synergistic amts. or in various
 dosages or at various time schedules. The invention also relates to kits
 and compns. concerning the combination of drugs.

IT 524084-27-3
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; immunostimulatory nucleic acids for the
 treatment of asthma and allergy)

L19 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 8
 ACCESSION NUMBER: 2003:241991 CAPLUS
 DOCUMENT NUMBER: 138:270283
 TITLE: Oligodeoxynucleotide and its use to induce an immune
 response
 INVENTOR(S): Klinman, Dennis; Verthelyi, Daniela; Ishii, Ken; Mond,
 James J.; Gursel, Mayda
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S.
 Ser. No. 958,713.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003060440	A1	20030327	US 2002-68160	20020206

PRIORITY APPLN. INFO.: US 1999-128898P P 19990412
 US 2001-958713 A2 20011011

ED Entered STN: 28 Mar 2003

AB D type CpG oligodeoxynucleotides are provided herein that include a

sequence represented by the following formula: 5'-
X1X2X3Pu1Py2CpGPu3Py4X4X5X6(W)M(G)N-3' wherein the central CpG motif is
unmethylated, Pu is a purine nucleotide, Py is a pyrimidine nucleotide, X
and W are any nucleotide, M is any integer from 0 to 10, and N is any
integer from 4 to 10. The oligodeoxynucleotides can activate immune
cells, such as antigen-presenting cells or natural killer cell, and/or can
stimulate prodn. of cytokines. Methods of using these
oligodeoxynucleotides to induce an immune response are provided. The
oligodeoxynucleotides can be used in treatment or amelioration of cancer,
allergy, autoimmune disease, immunodeficiency, or infection. They can
also be used to enhance the efficacy of vaccines.

- IT 503572-62-1 503572-63-2 503572-65-4
503572-66-5 503572-69-8 503572-73-4
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(CpG oligodeoxynucleotides for immunostimulation and immunotherapy of
various diseases)
- IT 503575-76-6 503575-92-6 503575-93-7
503575-94-8
RL: PRP (Properties)
(unclaimed nucleotide sequence; oligodeoxynucleotide and its use to
induce an immune response)
- IT 503576-63-4 503576-64-5 503576-65-6
RL: PRP (Properties)
(unclaimed sequence; oligodeoxynucleotide and its use to induce an
immune response)

L19 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 9
ACCESSION NUMBER: 2003:203398 CAPLUS
DOCUMENT NUMBER: 138:231727
TITLE: Immunostimulatory nucleic acid for treatment of
non-allergic inflammatory diseases
INVENTOR(S): Krieg, Arthur M.; Berg, Daniel J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 229 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003050268	A1	20030313	US 2002-112653	20020329

PRIORITY APPLN. INFO.: US 2001-279642P P 20010329
OTHER SOURCE(S): MARPAT 138:231727
ED Entered STN: 14 Mar 2003
AB The invention provides methods and compns. for using immunostimulatory
nucleic acids to treat non-allergic inflammatory diseases. Non-allergic
inflammatory diseases that may be treated according to the methods and
products of the invention include psoriasis and inflammatory bowel
disease. The invention further provides methods for augmenting a Th1
response to immunostimulatory nucleic acid involving inhibition of
prostaglandin-mediated counter-regulatory response.

IT 501983-30-8
RL: PRP (Properties)
(unclaimed nucleotide sequence; immunostimulatory nucleic acid for
treatment of non-allergic inflammatory diseases)

L19 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 10
ACCESSION NUMBER: 2003:878099 CAPLUS

DOCUMENT NUMBER: 140:58003
 TITLE: Antigenic Epitopes Fused to Cationic Peptide Bound to Oligonucleotides Facilitate Toll-Like Receptor 9-Dependent, but CD4+ T Cell Help-Independent, Priming of CD8+ T Cells
 AUTHOR(S): Schirmbeck, Reinhold; Riedl, Petra; Zurbriggen, Rinaldo; Akira, Shizuo; Reimann, Joerg
 CORPORATE SOURCE: Department of Medical Microbiology and Immunology, University of Ulm, Ulm, D-89081, Germany
 SOURCE: Journal of Immunology (2003), 171(10), 5198-5207
 CODEN: JOIMA3; ISSN: 0022-1767
 PUBLISHER: American Association of Immunologists
 DOCUMENT TYPE: Journal
 LANGUAGE: English

ED Entered STN: 10 Nov 2003

AB A priority in current vaccine research is the development of adjuvants that support the efficient priming of long-lasting, CD4+ T cell help-independent CD8+ T cell immunity. Oligodeoxynucleotides (ODN) with immune-stimulating sequences (ISS) contg. CpG motifs facilitate the priming of MHC class I-restricted CD8+ T cell responses to proteins or peptides. We show that the adjuvant effect of ISS+ ODN on CD8+ T cell priming to large, recombinant Ag is enhanced by binding them to short, cationic (arginine-rich) peptides that themselves have no adjuvant activity in CD8+ T cell priming. Fusing antigenic epitopes to cationic (8- to 10-mer) peptides bound to immune-stimulating ISS+ ODN or non-stimulating NSS+ ODN (without CpG-contg. sequences) generated immunogens that efficiently primed long-lasting, specific CD8+ T cell immunity of high magnitude. Different MHC class I-binding epitopes fused to short cationic peptides of different origins showed this adjuvant activity. Quant. ODN binding to cationic peptides strikingly reduced the toxicity of the latter, suggesting that it improves the safety profile of the adjuvant. CD8+ T cell priming supported by this adjuvant was Toll-like receptor 9 dependent, but required no CD4+ T cell help. ODN (with or without CpG-contg. sequences) are thus potent Th1-promoting adjuvants when bound to cationic peptides covalently linked to antigenic epitopes, a mode of Ag delivery prevailing in many viral nucleocapsids.

IT 637803-30-6

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ODN-DC19 with CpG-contg.; oligodeoxynucleotides as potent T cell priming adjuvants when bound to cationic peptides fused to antigenic epitopes)

REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 11

ACCESSION NUMBER: 2002:521467 CAPLUS
 DOCUMENT NUMBER: 137:88455
 TITLE: Inhibition of angiogenesis by nucleic acids
 INVENTOR(S): Bratzler, Robert L.
 PATENT ASSIGNEE(S): Coley Pharmaceutical Group, Inc., USA
 SOURCE: PCT Int. Appl., 276 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053141	A2	20020711	WO 2001-US48458	20011214
WO 2002053141	A3	20030522		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003055014 A1 20030320 US 2001-17995 20011214

PRIORITY APPLN. INFO.: US 2000-255534P P 20001214

OTHER SOURCE(S): MARPAT 137:88455

ED Entered STN: 12 Jul 2002

AB The invention provides methods and products for inhibiting angiogenesis. At least one antiangiogenic nucleic acid mol. is administered to a subject to prevent or treat unwanted angiogenesis. Non-nucleic acid antiangiogenic agents also can be administered.

IT 441364-86-9D, phosphorothioate linkage-contg.

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleic acids for inhibition of angiogenesis)

L19 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 12

ACCESSION NUMBER: 2002:369804 CAPLUS

DOCUMENT NUMBER: 137:19096

TITLE: Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide

AUTHOR(S): Gursel, Mayda; Verthelyi, Daniela; Gursel, Ihsan; Ishii, Ken J.; Klinman, Dennis M.

CORPORATE SOURCE: Section of Retroviral Research, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, 20892, USA

SOURCE: Journal of Leukocyte Biology (2002), 71(5), 813-820
CODEN: JLBIE7; ISSN: 0741-5400

PUBLISHER: Federation of American Societies for Experimental Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 19 May 2002

AB Synthetic oligodeoxynucleotides (ODN) expressing "CpG motifs" show promise as immune adjuvants, antiallergens, anticancer, and immunoprotective agents. Two structurally distinct classes of CpG ODN have been identified that stimulate human PBMC. This work establishes that both types of ODN bind to and are internalized by the same individual B cells, NK cells, and monocytes. However, the intracellular localization of "D" and "K" ODN differs, as does their functional activity: "K" type ODN trigger monocytes and B cells to proliferate and secrete IL-6 and IgM, whereas "D" type ODN induce NK cells to produce IFN- γ . and monocytes to differentiate into CD83+/CD86+ dendritic cells. In monocytes, these two types of ODN (which differ in backbone compn. and CpG motif) cross-inhibit one another's activity. Thus, different types of CpG ODN have distinct and in some cases incompatible effects on the same cells, a finding with important implications for the therapeutic use of these agents.

IT 434529-77-8

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide)

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 13

ACCESSION NUMBER: 2001:526086 CAPLUS
DOCUMENT NUMBER: 135:102560
TITLE: Oligodeoxynucleotide and its use to induce an immune response
INVENTOR(S): Klinman, Dennis; Ishii, Ken; Verthelyi, Daniela
PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001051500	A1	20010719	WO 2001-US1122	20010112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001027889	A5	20010724	AU 2001-27889	20010112
EP 1322655	A1	20030702	EP 2001-902045	20010112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2003144229	A1	20030731	US 2002-194035	20020712
PRIORITY APPLN. INFO.: US 2000-176115P P 20000114				
WO 2001-US1122 W 20010112				

ED Entered STN: 20 Jul 2001

AB The present invention provides a substantially pure or isolated oligodeoxynucleotide (ODN) of at least about 10 nucleotides comprising different CpG sequences, as well as an oligodeoxynucleotide delivery complex and a pharmacol. compn. comprising an ODN or ODNs, and a method of inducing an immune response by administering such an ODN or ODNs to a host.

IT 350271-02-2 350271-06-6 350271-08-8
350271-18-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oligodeoxynucleotide and its use to induce an immune response)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 14

ACCESSION NUMBER: 2001:507845 CAPLUS

DOCUMENT NUMBER: 135:103353

TITLE: A novel human growth factor betacellulin splice variant BTC-.beta. lacking C5-C6 disulfide loop, cDNA sequence, diagnostic and therapeutic uses

INVENTOR(S): Dunbar, Andrew Jeremy; Goddard, Christopher

PATENT ASSIGNEE(S): Gropep Limited, Australia

SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049845	A1	20010712	WO 2001-AU10	20010105

W: AU, CA, JP, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

PRIORITY APPLN. INFO.:

AU 2000-4969

A 20000106

ED Entered STN: 13 Jul 2001

AB The invention relates to a polynucleotide sequence encoding a naturally occurring splice variant of human betacellulin (BTC), designated BTC-.beta.. The polynucleotide sequence of the BTC-.beta. lacks the sequence encoding the last C5-C6 disulfide loop of the epidermal growth factor CX7CX4C10CX1CX8C motif, which is normally present in the gene encoding the authentic BTC. The BTC-.beta. may be used for treating conditions mediated or modulated by ErbB receptors. The invention also provides methods for producing the BTC-.beta. by recombinant DNA techniques and antibodies against the BTC-.beta..

IT 350270-01-8

RL: PRP (Properties)

(unclaimed sequence; novel human growth factor betacellulin splice variant BTC-.beta. lacking C5-C6 disulfide loop, cDNA sequence, diagnostic and therapeutic uses)

REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 15 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 15

ACCESSION NUMBER: 2001:247202 CAPLUS

DOCUMENT NUMBER: 134:279560

TITLE: Methods related to immunostimulatory nucleic acid-induced interferon

INVENTOR(S): Hartmann, Gunther; Bratzler, Robert L.; Krieg, Arthur

PATENT ASSIGNEE(S): Coley Pharmaceutical Group, Inc., USA; University of Iowa Research Foundation

SOURCE: PCT Int. Appl., 168 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001022990	A2	20010405	WO 2000-US26527	20000927
WO 2001022990	A3	20011004		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1220684	A2	20020710	EP 2000-965477	20000927
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

JP 2003510290	T2	20030318	JP 2001-526199	20000927
---------------	----	----------	----------------	----------

ZA 2002001959	A	20030310	ZA 2002-1959	20020308
---------------	---	----------	--------------	----------

PRIORITY APPLN. INFO.:

US 1999-156147P P 19990927

WO 2000-US26527 W 20000927

ED Entered STN: 06 Apr 2001

AB Methods and compns. are provided for extending the clin. utility of IFN-.alpha. in the treatment of a variety of viral and proliferative disorders. Among other aspects, the invention provides methods which increase the efficacy of IFN-.alpha. treatment and reduce IFN-.alpha. treatment-related side effects. In addn., methods are provides for supporting the survival and for activating natural interferon producing cells (IPCs)in vitro without exogenous IL-3 or GM-CSF. The invention is based on the discovery that certain CpG and non-CpG ISNAs promote survival and stimulation of IPCs.

IT 332956-63-5
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (immunostimulatory nucleic acids for improving efficacy and reducing side effects of interferon therapy against viral infection and proliferative disease)

L19 ANSWER 16 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 16
 ACCESSION NUMBER: 2001:247187 CAPLUS
 DOCUMENT NUMBER: 134:275762
 TITLE: Immunostimulatory nucleic acids
 INVENTOR(S): Krieg, Arthur M.; Schetter, Christian; Vollmer, Jorg
 PATENT ASSIGNEE(S): University of Iowa Research Foundation, USA; Coley Pharmaceutical G.m.b.H.
 SOURCE: PCT Int. Appl., 338 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001022972	A2	20010405	WO 2000-US26383	20000925
WO 2001022972	A3	20020117		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1221955	A2	20020717	EP 2000-965433	20000925
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000014236	A	20021015	BR 2000-14236	20000925
TR 200200797	T2	20021021	TR 2002-200200797	20000925
JP 2003510282	T2	20030318	JP 2001-526182	20000925
EE 200200158	A	20030616	EE 2002-158	20000925
NZ 517929	A	20040227	NZ 2000-517929	20000925
ZA 2002001963	A	20030310	ZA 2002-1963	20020308
BG 106538	A	20021229	BG 2002-106538	20020321
NO 2002001453	A	20020527	NO 2002-1453	20020322
US 2003212026	A1	20031113	US 2002-314578	20021209
PRIORITY APPLN. INFO.:			US 1999-156113P	P 19990925
			US 1999-156135P	P 19990927
			US 2000-227436P	P 20000823
			US 2000-669187	A1 20000925
			WO 2000-US26383	W 20000925

OTHER SOURCE(S): MARPAT 134:275762
 ED Entered STN: 06 Apr 2001

AB The invention relates to immunostimulatory nucleic acid compns. and methods of using the compns. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/or greater than 50% C nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids contg. CpG motifs. The invention also encompasses preferred CpG nucleic acids.

IT 331880-34-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunostimulatory nucleic acids)

L19 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 17

ACCESSION NUMBER: 2000:741930 CAPLUS

DOCUMENT NUMBER: 133:320986

TITLE: Oligodeoxynucleotide and its use to induce an immune response

INVENTOR(S): Klinman, Dennis; Ishii, Ken; Verthelyi, Daniela

PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061151	A2	20001019	WO 2000-US9839	20000412
WO 2000061151	A3	20010426		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1176966	A2	20020206	EP 2000-923283	20000412
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

PRIORITY APPLN. INFO.: US 1999-128898P P 19990412

WO 2000-US9839 W 20000412

ED Entered STN: 20 Oct 2000

AB The present invention provides a substantially pure or isolated oligodeoxynucleotide of at least about 10 nucleotides comprising a sequence represented by either the formula: 5' N1N2N3T-CpG-WN4N5N6 3' wherein the central CpG motif is unmethylated, W is A or T, and N1, N2, N3, N4, N5, and N6 are any nucleotides, or the formula: 5' RY-CpG-RY 3' wherein the central CpG motif is unmethylated, R is A or G, and Y is C or T, as well as an oligodeoxynucleotide delivery complex and a pharmacol. compn. comprising the present inventive oligodeoxynucleotide, and a method of inducing an immune response by administering the present inventive oligodeoxynucleotide to a host. The oligodeoxynucleotides with phosphate or phosphorothioate backbone modification are useful for inducing cell-mediated and humoral immune response and are therefore useful for treatment of allergy, asthma, cancer, autoimmune disease, immunol. disease, infection, and immune deficiency.

IT 301939-59-3D, phosphate or phosphorothioate derivs.

301939-63-9D, phosphate or phosphorothioate derivs.
 301939-65-1D, phosphate or phosphorothioate derivs.
 301939-75-3D, phosphate or phosphorothioate derivs.
 302865-84-5D, phosphate or phosphorothioate derivs.
 302865-85-6D, phosphate or phosphorothioate derivs.

RL: BSU (Biological study, unclassified); PRP (Properties); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oligodeoxynucleotide for use to induce immune response)

L19 ANSWER 18 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:142919 CAPLUS
 DOCUMENT NUMBER: 140:198064
 TITLE: Particulate immunostimulant
 INVENTOR(S): Van Nest, Gary; Tuck, Stephen
 PATENT ASSIGNEE(S): Dynavax Technologies Corporation, USA
 SOURCE: PCT Int. Appl., 90 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014322	A2	20040219	WO 2003-US25415	20030812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2002-402968P P 20020812

ED Entered STN: 22 Feb 2004

AB The authors disclose immunomodulatory compns. which comprise a cationic
 condensing agent, an immunomodulatory compd., and a stabilizing agent.
 The compns. of the invention typically form particles which have increased
 immunomodulatory activity as compared to immunomodulatory compds. not
 formulated in the compns. of the invention. Also provided are methods of
 making the compns. and methods for therapeutic use of the compns. In one
 example, interferon-.gamma. release by human mononuclear cells was shown
 to be enhanced by the combination of CpG oligonucleotide, polymyxin B, and
 Tween-80.

IT 662376-92-3

RL: PRP (Properties)
 (unclaimed sequence; particulate immunostimulant)

L19 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:451477 CAPLUS
 TITLE: Method of treating and preventing infections in
 immunocompromised subjects with immunostimulatory CpG
 oligonucleotides
 INVENTOR(S): Klinman, Dennis M.; Verthelyi, Daniela
 PATENT ASSIGNEE(S): The Government of the USA as Represented by the
 Secretary of the Dept. of Health & Human Services, USA
 SOURCE: U.S. Pat. Appl. Publ., 64 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004105872	A1	20040603	US 2003-666022	20030917
PRIORITY APPLN. INFO.:			US 2002-411944P	P 20020918

ED Entered STN: 04 Jun 2004

AB A method is disclosed herein for increasing an immune response to an opportunistic infection in an immunocompromised subject. In one embodiment, the subject is infected with a lentivirus. The method includes increasing an immune response to a pathogen using D oligodeoxynucleotides including a CpG motif. Addn. of K or D CpG oligodeoxynucleotides boosted the immunogenicity of the Engerix B hepatitis B virus vaccine to render refractory SIV-infected macaques responsive to vaccination.

IT **700878-94-0 700878-95-1 700878-96-2**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence, immunocompromised macaques response to HBV vaccine improvement with; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT **698400-46-3 698400-48-5 698400-54-3**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; immunostimulatory CpG oligonucleotides for treating and preventing infections in immunocompromised subjects)

IT **698753-95-6 698754-76-6 698754-77-7**
RL: PRP (Properties)
(unclaimed nucleotide sequence; method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides)

L19 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:511473 CAPLUS

DOCUMENT NUMBER: 139:79147

TITLE: Use of CpG oligodeoxynucleotides to induce angiogenesis

INVENTOR(S): Klinman, Dennis M.; Zheng, Mei; Rouse, Barry T.

PATENT ASSIGNEE(S): The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, USA; The University of Tennessee Research Corporation

SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003054161	A2	20030703	WO 2002-US40955	20021219
WO 2003054161	A3	20031030		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-343457P P 20011220

OTHER SOURCE(S): MARPAT 139:79147

ED Entered STN: 04 Jul 2003

AB This disclosure provides a method of inducing prodn. of vascular endothelial growth factor by a cell. The method includes contacting the cell with a CpG oligonucleotide, thereby inducing the prodn. of vascular endothelial growth factor by the cell. The disclosure further provides a method inducing neovascularization in a tissue. This method includes comprising introducing a CpG oligodeoxynucleotide into an area of the tissue wherein the formation of new blood vessels is desired, thereby inducing neovascularization in the area of the tissue.

IT 552439-49-3 552439-50-6 552439-53-9
552439-56-2 552439-61-9 552439-62-0
552439-63-1

RL: PRP (Properties)

(unclaimed nucleotide sequence; use of CpG oligodeoxynucleotides to induce angiogenesis)

L19 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:202770 CAPLUS

DOCUMENT NUMBER: 138:236936

TITLE: Differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides

INVENTOR(S): Klinman, Dennis M.; Gursel, Mayda; Verthelyi, Daniela

PATENT ASSIGNEE(S): The Government of the United States of America as Represented by the Secretary of Health and Human Services, USA

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020884	A2	20030313	WO 2002-US25732	20020813

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-312190P P 20010814

ED Entered STN: 14 Mar 2003

AB This disclosure relates to dendritic cells, specifically to the methods of generating mature dendritic cells using D type oligodeoxynucleotides including a CpG motif. The methods include contacting a dendritic cell precursor with a D ODN to generate a mature dendritic cell. In one specific, non-limiting example, the method includes contacting the

dendritic cell with an antigen. In another specific, non-limiting example, the method is a single step method wherein the D ODN is administered without other cytokines, such as GM-CSF and/or IL-4. These methods are of use both in vitro and in vivo. The findings disclosed herein document that mature DC can be rapidly and reproducibly generated by culturing PBMC or elutriated monocytes with D ODN in serum-free or conventional medium. These DC efficiently present antigen to autologous T cells in vitro and in vivo, and support the induction of Th1 biased immune responses. Without being bound by theory, the effect of D ODN on DC differentiation is dependent upon IFN.alpha. -secreting pDC being present during culture. Current results indicate that IFN.alpha. is necessary but not sufficient by itself to induce the differentiation of human monocytes into functionally active DC (Fig 2C). It is likely that functional differences between D and K type CpG ODN reflects differences in their recognition, uptake and/or processing by immune cells. These differences in uptake and activity have a structural basis. Whereas the immunostimulatory motif of a conventional ODN consists of a phosphorothioate TCGTT/A, the relevant motif in a D ODN consists of a phosphodiester purine/pyrimidine/CG/purine/pyrimidine hexamer (Verthelyi et al., J Immunol. 166: 2372-2377, 2001, which is incorporated herein by ref.). In addn., the hexamer of a D ODN is flanked by complementary bases that form a hairpin loop with the CpG dinucleotide at its apex - secondary structure that is absent from conventional CpG ODN. Finally, D but not K ODN are capped at the 3' end with a poly-G tail. This poly-G tail may interact with scavenger receptors on immune cells. D ODN reproducibly stimulated approx. 60 % of monocytes to differentiate into DC, as detd. phenotypically, histol. and functionally. The prodn. of IFN.alpha. by pDC present in culture contributed to this maturation (Fig 1A and 2B). The DC generated by D ODN are functionally active, as they promote antigen-specific immune responses in vitro and in vivo (Fig 3, 4, 5 and 6).

IT 501729-67-5 501729-68-6
 RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
 (ODN nucleotide sequence; differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

IT 501834-13-5 501834-14-6 501834-15-7
 501834-16-8 501834-25-9 501834-30-6
 501834-31-7 501834-32-8 501834-43-1 501834-44-2
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; differentiation of human monocytes into mature functional dendritic cells with CpG oligodeoxynucleotides)

L19 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:306455 CAPLUS
 DOCUMENT NUMBER: 139:159661
 TITLE: CpG Oligodeoxynucleotides Protect Normal and SIV-Infected Macaques from Leishmania Infection
 AUTHOR(S): Verthelyi, Daniela; Gursel, Mayda; Kenney, Richard T.; Lifson, Jeffrey D.; Liu, Shuying; Mican, Joan; Klinman, Dennis M.
 CORPORATE SOURCE: Center for Biologics Evaluation and Research, Section of Retroviral Immunology, Food and Drug Administration, Bethesda, MD, 20892, USA
 SOURCE: Journal of Immunology (2003), 170(9), 4717-4723
 CODEN: JOIMA3; ISSN: 0022-1767
 PUBLISHER: American Association of Immunologists
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 ED Entered STN: 22 Apr 2003
 AB Oligodeoxynucleotides contg. CpG motifs (CpG ODNs) mimic microbial DNA and

activate effectors of the innate immune response, which limits the spread of pathogens and promotes an adaptive immune response. CpG ODNs have been shown to protect mice from infection with intracellular pathogens. Unfortunately, CpG motifs that optimally stimulate humans are only weakly active in mice, mandating the use of nonhuman primates to monitor the activity and safety of "human" CpG ODNs in vivo. This study demonstrates that CpG ODN treatment of rhesus macaques significantly reduces the severity of the lesions caused by a challenge with Leishmania: Leishmania superinfection is common in immunocompromised hosts, particularly those infected with HIV. This study shows that PBMCs from HIV-infected subjects respond to stimulation with CpG ODNs. To det. whether CpG ODNs can protect retrovirus-infected primates, SIV-infected macaques were treated with CpG ODNs and then challenged with Leishmania: Both lesion size and parasite load were significantly reduced in the CpG-treated animals. These findings support the clin. development of CpG ODNs as immunoprotective agents in normal and HIV-infected patients.

IT 573722-80-2 573722-82-4 573722-83-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection)

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:975836 CAPLUS

DOCUMENT NUMBER: 140:75912

TITLE: IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences

AUTHOR(S): Duramad, Omar; Fearon, Karen L.; Chan, Jean H.; Kanzler, Holger; Marshall, Jason D.; Coffman, Robert L.; Barrat, Franck J.

CORPORATE SOURCE: Dynavax Technologies Corporation, Berkeley, CA, USA

SOURCE: Blood (2003), 102(13), 4487-4492

CODEN: BLOOAW; ISSN: 0006-4971

PUBLISHER: American Society of Hematology

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 15 Dec 2003

AB Immunostimulatory sequences (ISS) are short oligonucleotides contg. unmethylated cytosine-phosphate-guanine (CpG) dinucleotides that stimulate innate immune responses through Toll-like receptor-9 on B cells and plasmacytoid dendritic cell (PDC) precursors. The anti-inflammatory cytokine interleukin (IL)-10 is predicted to be a potent inhibitor of many of the activities described for ISS, and this may impact the use of ISS in disease states characterized by elevated IL-10. As the activities of ISS on PDCs are central to many clin. applications of ISS, we have studied the effects of IL-10 on PDC stimulation by 3 distinct classes of ISS. IL-10 inhibited cytokine prodn. and survival of ISS-activated PDCs; however, IL-12 induction was much more sensitive to inhibition than interferon (IFN)-.alpha. induction. Within the PDC population are cells that respond to ISS by producing either IL-12 or IFN-.alpha. but not both cytokines. IL-12-producing PDCs require costimulation through CD40 and appear more mature than IFN-.alpha.-producing PDCs. The 3 distinct classes of ISS differed with respect to induction of PDC maturation and T-cell priming capacity. IL-10 regulated PDC activation but did not inhibit the subsequent T-cell-priming ability of PDCs already activated by ISS.

IT 640803-43-6

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)

(IL-10 regulates plasmacytoid dendritic cell response to CpG-contg. immunostimulatory sequences)

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 24 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:229621 CAPLUS
 DOCUMENT NUMBER: 139:20882
 TITLE: Response of peripheral blood mononuclear cells from lupus patients to stimulation by CpG oligodeoxynucleotides
 AUTHOR(S): Zeuner, R. A.; Klinman, D. M.; Illei, G.; Yarboro, C.; Ishii, K. J.; Gursel, M.; Verthelyi, D.
 CORPORATE SOURCE: Center for Biologics Evaluation and Research/Food and Drug Administration, Bethesda, MD, 20892, USA
 SOURCE: Rheumatology (Oxford, United Kingdom) (2003), 42(4), 563-569
 CODEN: RUMAFK; ISSN: 1462-0324
 PUBLISHER: Oxford University Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 ED Entered STN: 25 Mar 2003
 AB Objectives: Increased levels of hypomethylated CpG-contg. DNA in sera from patients with systemic lupus erythematosus (SLE) may contribute to the initiation and/or perpetuation of the disease. This study characterizes the in vitro response of peripheral blood mononuclear cells (PBMC) from SLE patients to CpG DNA. Methods: Secretion of cytokines and IgM, cell proliferation and up-regulation of co-stimulatory mols. were evaluated in PBMC from SLE patients and normal controls after stimulation with synthetic oligodeoxynucleotides (ODN) contg. CpG motifs. Results: Up-regulation of co-stimulatory mols. and the secretion of interferon-.alpha. and interleukin-6 (IL-6) in response to CpG ODN was significantly reduced in monocytes and dendritic cells from SLE patients. Secretion of interferon-.gamma. by natural killer (NK) cells was also reduced. In contrast, the IgM and IL-10 response of B cells to CpG ODN was normal. Conclusion: Monocytes, dendritic cells and NK cells from SLE patients respond abnormally to CpG ODN stimulation, which may contribute to the cytokine imbalance obsd. in SLE.
 IT 537058-58-5 537058-59-6
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (monocytes, dendritic cells and NK cells from lupus patients respond to CpG oligodeoxynucleotides stimulation and contribute to the cytokine imbalance)

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:122818 CAPLUS
 DOCUMENT NUMBER: 136:182447
 TITLE: Vaccine against respiratory syncytial virus (RSV)
 INVENTOR(S): Mond, James J.; Prince, Gregory; Klinman, Dennis M.
 PATENT ASSIGNEE(S): Henry M. Jackson Foundation for the Advancement of Military Medicine, USA
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002011761	A2	20020214	WO 2001-US41633	20010809
WO 2002011761	A3	20030123		

W: AU, CA, JP, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, TR

AU 2001085421 A5 20020218 AU 2001-85421 20010809
PRIORITY APPLN. INFO.: US 2000-224011P P 20000810
US 2000-229307P P 20000901
WO 2001-US41633 W 20010809

ED Entered STN: 15 Feb 2002

AB The present invention relates to a vaccine comprising adjuvanting oligodeoxynucleotides (ODNs), contg. at least one CpG dinucleotide and an antigen comprising a peptide sequence bearing at least one epitope of a Paramyxoviridae F protein. In one embodiment, the ODN is admixed or conjugated to an F protein from a respiratory syncytial virus (RSV). The vaccine of the invention may be administered directly to mucosal tissues of the respiratory tract by inhalation or intranasal administration.

IT 400186-43-8 400186-47-2 400186-49-4
400186-59-6

RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vaccine compns. comprising Paramyxoviridae F protein epitopes and immunostimulatory oligonucleotides against respiratory syncytial virus)

L19 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:737476 CAPLUS

DOCUMENT NUMBER: 137:231323

TITLE: CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells

AUTHOR(S): Gursel, Mayda; Verthelyi, Daniela; Klinman, Dennis M.

CORPORATE SOURCE: Section of Retroviral Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, 20892, USA

SOURCE: European Journal of Immunology (2002), 32(9), 2617-2622

CODEN: EJIMAF; ISSN: 0014-2980

PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 29 Sep 2002

AB Dendritic cells (DC) excel at presenting antigen to T cells and thus make a key contribution to the induction of primary and secondary immune responses. DC matured in vitro and pulsed with antigen show promise for the immunotherapy of cancer and infectious diseases. Synthetic oligonucleotides (ODN) expressing immunomodulatory "CpG motifs" were found to boost APC function in mice. Current results demonstrate that the recently identified "D" type of CpG ODN stimulate human peripheral blood monocytes to mature into functionally active DC over 2-4 days. The transition from monocyte to DC is characterized by the upregulation of CD83, CD86, CD80, CD40 and the down-regulation of CD14. These DC support antigen-specific humoral and cellular responses in vitro and in vivo. The differentiation of these monocytes is mediated by plasmacytoid DC, which respond to D type ODN by secreting IFN-.alpha.. Since D type CpG motifs are present in bacterial and viral DNA, the maturation of monocytes into functional DC may reflect a physiol. response that can be harnessed therapeutically through the use of CpG ODN.

IT 459471-16-0 459471-17-1

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells)

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:124395 CAPLUS

DOCUMENT NUMBER: 136:293135

TITLE: CpG oligodeoxynucleotides as vaccine adjuvants in primates

AUTHOR(S): Verthelyi, Daniela; Kenney, Richard T.; Seder, Robert A.; Gam, Albert A.; Friedag, Brenda; Klinman, Dennis M.

CORPORATE SOURCE: Division of Viral Products, Center for Biologics Evaluation and Research/Food and Drug Administration, Bethesda, MD, 20892, USA

SOURCE: Journal of Immunology (2002), 168(4), 1659-1663

CODEN: JOIMA3; ISSN: 0022-1767

PUBLISHER: American Association of Immunologists

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 17 Feb 2002

AB Synthetic oligodeoxynucleotides (ODN) contg. unmethylated CpG motifs act as immune adjuvants in mice, boosting the humoral and cellular response to coadministered Ags. CpG ODN that stimulate human PBMC are only weakly active in mice. Thus, alternative animal models are needed to monitor the activity and safety of "human" CpG ODN in vivo. This work demonstrates that rhesus macaques recognize and respond to the same CpG motifs that trigger human immune cells. Coadministering CpG ODN with heat-killed Leishmania vaccine provided significantly increased protection of macaques against cutaneous Leishmania infection. These findings indicate that rhesus macaques provide a useful model for studying the in vivo activity of human CpG motifs, and that ODN expressing these motifs act as strong immune adjuvants.

IT 406966-34-5 406966-35-6

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CpG oligodeoxynucleotides as vaccine adjuvants in primates)

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:903912 CAPLUS

DOCUMENT NUMBER: 136:52708

TITLE: Immunostimulatory RNA/DNA hybrid molecules

INVENTOR(S): Mond, James J.; Flora, Michael; Klinman, Dennis M.

PATENT ASSIGNEE(S): Biosynexus Incorporated, USA

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001093902	A2	20011213	WO 2001-US18276	20010607
WO 2001093902	A3	20020418		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1292331 A2 20030319 EP 2001-941989 20010607
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2004052763 A1 20040318 US 2001-874991 20010607
 PRIORITY APPLN. INFO.: US 2000-209797P P 20000607
 WO 2001-US18276 W 20010607
 ED Entered STN: 14 Dec 2001
 AB The present invention provides immunol. compns. and methods relating to
 immunostimulatory intra-strand DNA/RNA hybrid oligonucleotides (HDRs),
 optimally encoding one or more CpG motif, which may be an unmethylated CpG
 motif. Administration of these compds., alone or in the context of one or
 more target antigens, promotes innate and antigen specific immunities.
 IT 381260-42-0 381260-99-7 381261-01-4
 381261-05-8 381261-06-9 381261-07-0
 381261-08-1 381261-17-2 381261-19-4
 RL: PRP (Properties)
 (unclaimed nucleotide sequence; immunostimulatory RNA/DNA hybrid mols.)

L19 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:125171 CAPLUS
 DOCUMENT NUMBER: 134:294478
 TITLE: Human peripheral blood cells differentially recognize
 and respond to two distinct CpG motifs
 AUTHOR(S): Verthelyi, Daniela; Ishii, Ken J.; Gursel, Mayda;
 Takeshita, Fumihiko; Klinman, Dennis M.
 CORPORATE SOURCE: Section of Retroviral Research, Center for Biologics
 Evaluation and Research, Food and Drug Administration,
 Bethesda, MD, 20892, USA
 SOURCE: Journal of Immunology (2001), 166(4), 2372-2377
 CODEN: JOIMA3; ISSN: 0022-1767
 PUBLISHER: American Association of Immunologists
 DOCUMENT TYPE: Journal
 LANGUAGE: English

ED Entered STN: 21 Feb 2001
 AB Oligodeoxynucleotides (ODN) that contain unmethylated CpG dinucleotides
 trigger a strong innate immune response in vertebrates. CpG ODN show
 promise as vaccine adjuvants, anti-allergens, and immunoprotective agents
 in animal models. Their transition to clin. use requires the
 identification of motifs that are optimally stimulatory in humans. Anal.
 of hundreds of novel ODN resulted in the identification and
 characterization of two structurally distinct "clusters" of
 immunostimulatory CpG ODN. One cluster ("D") preferentially stimulates
 IFN-.gamma. prodn. by NK cells, whereas the other ("K") stimulates cell
 proliferation and the prodn. of IL-6 and IgM by monocytes and B cells.
 The distinct immunostimulatory properties of K and D ODN can improve the
 design of CpG-based products to achieve specific therapeutic goals.
 IT 334074-91-8 334074-92-9
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); BIOL (Biological study)
 (two distinct CpG motifs in stimulation of human peripheral blood
 cells)

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2001:129322 CAPLUS
 DOCUMENT NUMBER: 135:302807
 TITLE: Response of porcine peripheral blood mononuclear cells
 to CpG-containing oligodeoxynucleotides
 AUTHOR(S): Kamstrup, S.; Verthelyi, D.; Klinman, D. M.
 CORPORATE SOURCE: Department for Pathobiology and Diagnostics, Danish
 Veterinary Institute for Virus Research, Kalvehave,

SOURCE: Lindholm, DK-4771, Den.
Veterinary Microbiology (2001), 78(4), 353-362
CODEN: VMICDQ; ISSN: 0378-1135

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 21 Feb 2001

AB Exposure to bacterial DNA generates a "danger signal" that stimulates cellular elements of the mammalian immune system to proliferate and/or secrete cytokines. Stimulation is critically dependent on hexameric motifs that contain an unmethylated CpG dinucleotide: these are commonly found in bacterial but not vertebrate DNA. Different motifs are optimally stimulatory in different species. This work examines whether oligodeoxynucleotides (ODNs) contg. CpG motifs stimulate peripheral blood mononuclear cells from pigs. Results show that pigs respond to CpG ODN by proliferating and secreting IL-6, IL-12 and TNF-.alpha.. By screening a large panel (>100) of ODNs, the palindromic hexamer 'ATCGAT' was identified as being optimally active in all animals examd. (N=10). These findings are the first to establish the immunostimulatory activity of CpG ODN in pigs, and suggest that the therapeutic uses envisioned for these ODNs (as vaccine adjuvants and immunoprotective agents) may be applicable to husbandry animals.

IT 366065-16-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(response of porcine peripheral blood mononuclear cells to CpG-contg. oligodeoxynucleotides)

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1988:418981 CAPLUS

DOCUMENT NUMBER: 109:18981

TITLE: Base sequence effects in double-helical DNA. III.
Average properties of curved DNA

AUTHOR(S): Maroun, Rachid C.; Olson, Wilma K.

CORPORATE SOURCE: Dep. Chem., Rutgers State Univ. New Jersey, New Brunswick, NJ, 08903, USA

SOURCE: Biopolymers (1988), 27(4), 585-603
CODEN: BIPMAA; ISSN: 0006-3525

DOCUMENT TYPE: Journal

LANGUAGE: English

ED Entered STN: 22 Jul 1988

AB The matrix-generator methods set forth in the preceding paper for treating rodlike DNA are adapted here to the calcn. of av. chain extension, macroscopic flexibility, and terminal residue orientation in curved duplexes. The different characteristics of curved vs. rodlike chains are illustrated with the hypotheticalal poly[d(A5G5)] .cntdot. poly[d(T5C5)] duplex. The curved helix is both more compact and macroscopically stiffer than either the poly(dA) .cntdot. poly(dT) or the poly(dG) .cntdot. poly(dC) chain. The calcns. were also extended to simple repetitive DNA sequences generated by synthetic ligation studies and the computed av. chain properties compared with obsd. gel mobilities. The predicted chain extension is also checked against the measured persistence lengths of the rodlike poly[d(GC)] and poly[d(AT)] alternating copolymers, and the known cyclization tendencies of selected repeating sequences. Chains are generated from local potential energy maps describing the morphol. and flexibility of adjacent base pairs. The energy maps, while approx., are more accurate descriptors of local structure than many of the intuitive models of DNA curvature offered to date. According to the energy surfaces, the intrinsic bending of curved DNA can be traced to asymmetry

in the bending of the guanosine and cytidine residues that join half-helical turn stretches of adenines in these chains. The oligo (A) stretches are analogous to residues of a perfectly elastic DNA that bend with equal likelihood in opposing directions. In other models of DNA curvature, the (G .cntdot. C) base pairs are presumed to adopt the classical B-DNA structure, whereas the (A .cntdot. T) base pairs are thought to be in some perturbed conformation.

IT 115013-80-4 115013-83-7

RL: BIOL (Biological study)

(flexibility and bending tendencies and dimensions of, calcn. of)

L19 ANSWER 32 OF 37 USPATFULL on STN

ACCESSION NUMBER: 2004:69536 USPATFULL

TITLE: Immunostimulatory RNA/DNA hybrid molecules

INVENTOR(S): Mond, James J., Silver Spring, MD, UNITED STATES

Flora, Michael, Mt. Airy, MD, UNITED STATES

Klinman, Dennis M., Potomac, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004052763	A1	20040318
APPLICATION INFO.:	US 2001-874991	A1	20010607 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-209797P	20000607 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5120	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides immunological compositions and methods relating to immunostimulatory intra-strand DNA/RNA hybrid oligonucleotides (HDRs), optimally encoding one or more CpG motif, which may be an unmethylated CpG motif. Administration of these compounds, alone or in the context of one or more target antigens, promotes innate and antigen specific immunities.

IT 381260-42-0 381260-99-7 381261-01-4

381261-05-8 381261-06-9 381261-07-0

381261-08-1 381261-17-2 381261-19-4

(unclaimed nucleotide sequence; immunostimulatory RNA/DNA hybrid mols.)

L19 ANSWER 33 OF 37 USPATFULL on STN

ACCESSION NUMBER: 2003:300800 USPATFULL

TITLE: Immunostimulatory nucleic acids

INVENTOR(S): Krieg, Arthur M., Wellesley, MA, UNITED STATES

Schetter, Christian, Hilden, GERMANY, FEDERAL REPUBLIC OF

Vollmer, Jorg, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): University of Iowa Research Foundation, Iowa City, IA, 52242 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003212026	A1	20031113
APPLICATION INFO.:	US 2002-314578	A1	20021209 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-669187, filed on 25 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-156113P	19990925 (60)
	US 1999-156135P	19990927 (60)
	US 2000-227436P	20000823 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Maria A. Trevisan, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210	
NUMBER OF CLAIMS:	106	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	11893	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/or greater than 50% c nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids containing CpG motifs. The invention also encompasses preferred CpG nucleic acids.	
IT	331880-34-3 (immunostimulatory nucleic acids)	

L19 ANSWER 34 OF 37 USPATFULL on STN
 ACCESSION NUMBER: 2003:283122 USPATFULL
 TITLE: Chimeric immunomodulatory compounds and methods of using the same - 11
 INVENTOR(S): Fearon, Karen L., Lafayette, CA, UNITED STATES
 Dina, Dino, Oakland, CA, UNITED STATES
 Tuck, Stephen F., Oakland, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199466	A1	20031023
APPLICATION INFO.:	US 2002-177826	A1	20020621 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-299883P	20010621 (60)
	US 2002-375253P	20020423 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Randolph T. Apple, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304-1018	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	7228	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.	
IT	482663-88-7P 482663-89-8P (chimeric immunomodulatory compds. comprising nucleic acids linked through dendrimer or polysaccharide spacer and antigen for treating allergy, infection or cancer)	

L19 ANSWER 35 OF 37 USPATFULL on STN
 ACCESSION NUMBER: 2003:250945 USPATFULL
 TITLE: Chimeric immunomodulatory compounds and methods of using the same - I

INVENTOR(S): Fearon, Karen L., Lafayette, CA, UNITED STATES
Dina, Dino, Oakland, CA, UNITED STATES
Tuck, Stephen F., Oakland, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003175731	A1	20030918
APPLICATION INFO.:	US 2002-176883	A1	20020621 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-299883P	20010621 (60)
	US 2002-375253P	20020423 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Randolph T. Apple, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304-1018	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	7092	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.

IT **482663-88-7P 482663-89-8P**
(chimeric immunomodulatory compds. comprising nucleic acids linked through dendrimer or polysaccharide spacer and antigen for treating allergy, infection or cancer)

L19 ANSWER 36 OF 37 USPATFULL on STN

ACCESSION NUMBER: 2003:214333 USPATFULL
TITLE: Combination motif immune stimulatory oligonucleotides with improved activity
INVENTOR(S): Krieg, Arthur M., Wellesley, MA, UNITED STATES
Vollmer, Jorg, Duesseldorf, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003148976	A1	20030807
APPLICATION INFO.:	US 2002-224523	A1	20020819 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-313273P	20010817 (60)
	US 2002-393952P	20020703 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2211	
NUMBER OF CLAIMS:	72	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	29 Drawing Page(s)	
LINE COUNT:	3159	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A class of immunostimulatory nucleic acids having at least two functionally and structurally defined domains is provided. This class of combination motif immunostimulatory nucleic acids activates an immune response and is useful for treating a variety of immune related disorders such as cancer, infectious disease, and allergic disorders. The nucleic acids also stimulate activation of natural killer cells and production of type 1 interferon.

IT 500239-90-7
(unclaimed nucleotide sequence; oligonucleotides contg. stimulatory phosphorothioate motif and neutralizing motif for treating infections, allergies and cancers)

L19 ANSWER 37 OF 37 USPATFULL on STN

ACCESSION NUMBER: 2003:79087 USPATFULL
TITLE: Inhibition of angiogenesis by nucleic acids
INVENTOR(S): Bratzler, Robert L., Concord, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003055014	A1	20030320
APPLICATION INFO.:	US 2001-17995	A1	20011214 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-255534P	20001214 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Maria A. Trevisan, c/o Wolf, Greenfield & Sacks, P.C., Federal Reserve Plaza, 600 Atlantic Avenue, Boston, MA, 02210	
NUMBER OF CLAIMS:	74	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	3268	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methods and products for inhibiting angiogenesis. At least one antiangiogenic nucleic acid molecule is administered to a subject to prevent or treat unwanted angiogenesis. Non-nucleic acid antiangiogenic agents also can be administered.

IT 441364-86-9D, phosphorothioate linkage-contg.
(nucleic acids for inhibition of angiogenesis)

FILE 'HOME' ENTERED AT 14:56:07 ON 01 JUL 2004